var title_f6_20_6464="IVUS extent coronary calcium";
var content_f6_20_6464=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56480&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56480&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intracoronary ultrasound shows the extent of coronary artery calcification",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 153px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intracoronary ultrasound is useful for establishing the presence and extent of coronary artery calcification. The top panel shows a small region of calcification (arrow) while the bottom panel shows a lumen that is completely surrounded by calcium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Yock P, Fitzgerald P, Popp R. Science and Medicine 1995: 2:68.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_20_6464=[""].join("\n");
var outline_f6_20_6464=null;
var title_f6_20_6465="Ligation of mesenteric vessels for right hemicolectomy";
var content_f6_20_6465=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F73546&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F73546&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ligation of mesenteric vessels for right hemicolectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 467px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The figure depicts the lymphovascular bundle at the root of the mesentery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_20_6465=[""].join("\n");
var outline_f6_20_6465=null;
var title_f6_20_6466="Patient information: Placenta previa (The Basics)";
var content_f6_20_6466=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83440\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/20/7495\">",
"         Pregnancy terms",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?16/21/16723\">",
"         Patient information: C-section (cesarean delivery) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/62/8163\">",
"         Patient information: What to expect in the NICU (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?11/45/11988\">",
"         Patient information: C-section (cesarean delivery) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Placenta previa (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/placenta-previa-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H103098955\">",
"      <span class=\"h1\">",
"       What is placenta previa?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Placenta previa is a condition that happens in pregnant women when the placenta covers the opening of the cervix. Normally, the placenta is not near the cervix (",
"      <a class=\"graphic graphic_figure graphicRef82935 \" href=\"UTD.htm?7/20/7495\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Placenta previa can cause severe bleeding from the vagina.",
"     </p>",
"     <p>",
"      Placenta previa is more likely in women who:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Had more than 1 c-section &ndash; A c-section is a type of surgery used to deliver a baby. It is also called a &ldquo;cesarean delivery.&rdquo;",
"       </li>",
"       <li>",
"        Had placenta previa in an earlier pregnancy",
"       </li>",
"       <li>",
"        Had 1 or more &ldquo;D and C&rdquo; procedures &ndash; In this procedure, a doctor scrapes the uterus to take out tissue.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Other things that can make placenta previa more likely are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Smoking",
"       </li>",
"       <li>",
"        Giving birth several times before",
"       </li>",
"       <li>",
"        Being pregnant with more than 1 baby at a time",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H103098970\">",
"      <span class=\"h1\">",
"       What are the symptoms of placenta previa?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most women leak blood from the vagina. In some women, the uterus also tightens. Doctors call this &ldquo;contractions.&rdquo; The belly can feel hard during contractions.",
"     </p>",
"     <p>",
"      A few women do not have any symptoms of placenta previa.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H103098985\">",
"      <span class=\"h1\">",
"       Is there a test for placenta previa?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or midwife can order a test called an &ldquo;ultrasound.&rdquo; This is an imaging test that creates pictures of the baby inside the woman&rsquo;s body. It also shows the placenta.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H103099000\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you are pregnant and leaking blood from your vagina, call your doctor, nurse, or midwife right away.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H103099015\">",
"      <span class=\"h1\">",
"       How is placenta previa treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor, nurse, or midwife will tell you not to have sex. Sex can make the placenta previa bleed. Putting anything deep in the vagina can make the placenta previa bleed.",
"     </p>",
"     <p>",
"      Treatment depends on your symptoms and how far along you are in your pregnancy. If placenta previa does not cause bleeding, you might have an ultrasound every 4 weeks to check it. The placenta sometimes moves into a normal position.",
"     </p>",
"     <p>",
"      If you have a placenta previa that is bleeding, even a little bit, you need treatment in the hospital right away. Your doctor or midwife will:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Check your heart rate and blood pressure &ndash; He or she will also check the baby&rsquo;s heart rate. &nbsp;",
"       </li>",
"       <li>",
"        Check how much you are bleeding. &nbsp;",
"       </li>",
"       <li>",
"        Give you fluids through an &ldquo;IV&rdquo; &ndash; This is a thin tube that goes into a vein. The fluids help keep your blood flow and blood pressure as normal as possible.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If the bleeding is heavy and does not slow down, your doctor might:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Give you a blood transfusion &ndash; This is when you get blood that was donated by another person. &nbsp;",
"       </li>",
"       <li>",
"        Deliver the baby with a c-section, even if it means the baby comes early.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Most women who have placenta previa do not need to deliver the baby the first time they have bleeding. Some women might need to stay in the hospital until they give birth, but other women can go home when the bleeding stops. While you are in the hospital, your doctor or midwife might give you:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Iron pills, if you lost a lot of blood",
"       </li>",
"       <li>",
"        Steroid medicines &ndash; These help the baby&rsquo;s lungs get ready for birth, if it could be born early. You do not need these medicines if you are 34 weeks pregnant or more or do not have symptoms. The steroids are not the same as the ones athletes take to build muscle.",
"       </li>",
"       <li>",
"        A shot of &ldquo;Rh immune globulin&rdquo; if your blood cells do not have a protein called &ldquo;Rh factor.&rdquo;",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If the placenta previa does not go away, your doctor will deliver the baby with a c-section about 1 month before your due date. This is because labor and vaginal delivery with placenta previa will cause severe bleeding. This is dangerous for you and your baby.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H103099030\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/21/16723?source=see_link\">",
"       Patient information: C-section (cesarean delivery) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/62/8163?source=see_link\">",
"       Patient information: What to expect in the NICU (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/45/11988?source=see_link\">",
"       Patient information: C-section (cesarean delivery) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?6/20/6466?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83440 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-8AB89F2CF9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_20_6466=[""].join("\n");
var outline_f6_20_6466=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H103098955\">",
"      What is placenta previa?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H103098970\">",
"      What are the symptoms of placenta previa?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H103098985\">",
"      Is there a test for placenta previa?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H103099000\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H103099015\">",
"      How is placenta previa treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H103099030\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83440\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/20/7495\">",
"      Pregnancy terms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/45/11988?source=related_link\">",
"      Patient information: C-section (cesarean delivery) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/21/16723?source=related_link\">",
"      Patient information: C-section (cesarean delivery) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/62/8163?source=related_link\">",
"      Patient information: What to expect in the NICU (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_20_6467="Photo birth 5";
var content_f6_20_6467=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65504&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65504&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Delivery sequence from crowning through birth of the newborn",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 290px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The shoulders are born. Notice how the head has turned to line up with the shoulders-the cardinal movement of external rotation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wolters Kluwer. Copyright &copy;2009.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_20_6467=[""].join("\n");
var outline_f6_20_6467=null;
var title_f6_20_6468="LIP with germinal centers";
var content_f6_20_6468=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lymphocytic interstitial pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 242px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power photomicrograph shows an interstitial infiltrate of lymphocytes, plasma cells, and histiocytes and the presence of germinal centers.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Colby TV, Koss MN, Travis WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_20_6468=[""].join("\n");
var outline_f6_20_6468=null;
var title_f6_20_6469="Bacitracin: Drug information";
var content_f6_20_6469=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bacitracin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?1/56/1925?source=see_link\">",
"    see \"Bacitracin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/63/33779?source=see_link\">",
"    see \"Bacitracin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F138673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Baciguent&reg; [OTC];",
"     </li>",
"     <li>",
"      BACiiM&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F138674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Baciguent&reg;;",
"     </li>",
"     <li>",
"      Baciject&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F138695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Miscellaneous;",
"     </li>",
"     <li>",
"      Antibiotic, Ophthalmic;",
"     </li>",
"     <li>",
"      Antibiotic, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F138676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not administer I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Clostridium difficile",
"      </i>",
"     </b>",
"     <b>",
"      -associated diarrhea (unlabeled use):",
"     </b>",
"     25,000 units 4 times/day for 7-10 days (Dudley 1986; Young, 1985).",
"     <b>",
"      Note:",
"     </b>",
"     May be considered when other more established regimens (eg, metronidazole or vancomycin) fail; not routinely used (Cohen, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Enteric VRE eradication (unlabeled use):",
"     </b>",
"     25,000 units 4 times/day for 7-10 days (Chia, 1995; O&rsquo;Donovan, 1994)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Superficial dermal infection:",
"     </b>",
"     Topical: Apply 1-3 times/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ophthalmic infection:",
"     </b>",
"     Ophthalmic (ointment): Instill",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     &rdquo; to",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     &rdquo; ribbon every 3-4 hours into conjunctival sac for acute infections, or 2-3 times/day for mild-to-moderate infections for 7-10 days.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F138688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/63/33779?source=see_link\">",
"      see \"Bacitracin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not administer I.V.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of infection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Infants:",
"     </i>",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &le;2.5 kg: 900 units/kg/day in 2-3 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;2.5 kg: 1000 units/kg/day in 2-3 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Superficial dermal infection:",
"     </b>",
"     Topical: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ophthalmic infection:",
"     </b>",
"     Ophthalmic (ointment): Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F138677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F138653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 50,000 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BACiiM&trade;: 50,000 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, ophthalmic: 500 units/g (3.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical, as zinc [strength expressed as base]: 500 units/g (0.9 g, 15 g, 30 g, 120 g, 454 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Baciguent&reg;: 500 units/g (30 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F138638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F138656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For I.M. administration only,",
"     <b>",
"      do not administer I.V.",
"     </b>",
"     Confirm any orders for parenteral use. Administer to upper outer quadrant of the buttocks; rotate administration site. The pH of urine should be kept &gt;6 by using sodium bicarbonate.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F138654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of susceptible bacterial infections mainly (has activity against gram-positive bacilli); due to toxicity risks, systemic and irrigant uses of bacitracin should be limited to situations where less toxic alternatives would not be effective",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F138692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral administration: Treatment of",
"     <i>",
"      Clostridium difficile",
"     </i>",
"     -associated diarrhea; has been used for enteric eradication of vancomycin-resistant enterococci (VRE)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F138702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Bacitracin may be confused with Bactrim&trade;, Bactroban&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F138693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension, edema of the face/lips, chest tightness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash, itching",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, nausea, vomiting, diarrhea, rectal itching",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Blood dyscrasias",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Nephrotoxicity (with systemic administration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1%: Rare cases of anaphylaxis have been reported in association with topical and intraoperative exposures.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F138660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to bacitracin or any component of the formulation; I.M. use is contraindicated in patients with renal impairment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F138642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis: Use with caution in patients who have been previously exposed to bacitracin; anaphylactic reactions have occurred on repeat exposure especially with irrigation use (eg, Damm, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal failure:",
"     <b>",
"      [U.S. Boxed Warning]: I.M. use may cause renal failure due to tubular and glomerular necrosis; monitor renal function daily.",
"     </b>",
"     Avoid concurrent use with other nephrotoxic drugs; discontinue use if toxicity occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate administration: Do not administer intravenously because severe thrombophlebitis occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Topical anti-infective (self-medication, OTC use): Use longer than 1 week is not recommended unless directed by prescriber. Seek advice from healthcare provider prior to use for deep puncture wounds, bites, or burns.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F138647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6140224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is unknown if bacitracin crosses the placenta. The minimal absorption after topical use should limit the amount of medication available for transfer to the fetus. If ophthalmic agents are needed during pregnancy, the minimum effective dose should be used in combination with punctual occlusion to decrease potential exposure to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6140235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is unknown if bacitracin is distributed in human milk. The minimal absorption after topical use should limit the amount of medication available for transfer.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F138663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Baciguent External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 units/g (28.35 g): $8.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Bacitracin External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 units/g (30 g): $2.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Bacitracin Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 units/g (3.5 g): $69.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Bacitracin Zinc External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 units/g (15 g): $3.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Bacitraycin Plus External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 units/g (28 g): $4.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Bacitracin Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50000 unit (1): $13.85",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F138651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.M.: Urinalysis, renal function tests",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F138664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Glubacida (MX);",
"     </li>",
"     <li>",
"      Nebacetina (MX);",
"     </li>",
"     <li>",
"      Neosporin D&eacute;rmico (MX);",
"     </li>",
"     <li>",
"      Polixin Ungena (MX);",
"     </li>",
"     <li>",
"      Tribiot (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F138641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by preventing transfer of mucopeptides into the growing cell wall",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F138659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Poor from mucous membranes and intact or denuded skin; rapidly following I.M. administration; not absorbed by bladder irrigation, but absorption can occur from peritoneal or mediastinal lavage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: CSF: Nil even with inflammation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: Minimal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: I.M.: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (10% to 40%) within 24 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chia JK, Nakata MM, Park SS, et al, &ldquo;Use of Bacitracin Therapy for Infection Due to Vancomycin-Resistant",
"      <i>",
"       Enterococcus faecium",
"      </i>",
"      ,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 1995, 21(6):1520.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/20/6469/abstract-text/8749657/pubmed\" id=\"8749657\" target=\"_blank\">",
"        8749657",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen SH, Gerding DN, Johnson S, et al, &ldquo;Clinical Practice Guidelines for",
"      <i>",
"       Clostridium difficile",
"      </i>",
"      Infection in Adults: 2010 Update by the Society for healthcare Epidemiology of American (SHEA) and the Infectious Diseases Society of America (IDSA),",
"      <i>",
"       Infect Control Hosp Epidemiol",
"      </i>",
"      , 2010, 31(5):431-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/20/6469/abstract-text/20307191/pubmed\" id=\"20307191\" target=\"_blank\">",
"        20307191",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Damm S, &ldquo;Intraoperative Anaphylaxis Associated With Bacitracin Irrigation,&rdquo;",
"      <i>",
"       Am J Health-Syst Pharm",
"      </i>",
"      , 2011, 68(4):323-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/20/6469/abstract-text/21289327/pubmed\" id=\"21289327\" target=\"_blank\">",
"        21289327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dudley MN, McLaughlin JC, Carrington G, et al, &ldquo;Oral Bacitracin vs Vancomycin Therapy for",
"      <i>",
"       Clostridium difficile",
"      </i>",
"      -Induced Diarrhea. A Randomized Double-Blind Trial,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1986, 146(6):1101-4.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Katz BE and Fisher AA, &ldquo;Bacitracin: A Unique Topical Antibiotic Sensitizer,&rdquo;",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 1987, 17(6):1016-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/20/6469/abstract-text/2963037/pubmed\" id=\"2963037\" target=\"_blank\">",
"        2963037",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kelly CP, Pothoulakis C, and LaMont JT, &ldquo;",
"      <i>",
"       Clostridium difficile",
"      </i>",
"      Colitis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1994, 330(4):257-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/20/6469/abstract-text/8043060/pubmed\" id=\"8043060\" target=\"_blank\">",
"        8043060",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mondy KE, Shannon W, and Mundy LM, &ldquo;Evaluation of Zinc Bacitracin Capsules Versus Placebo for Enteric Eradication of Vancomycin-Resistant",
"      <i>",
"       Enterococcus faecium",
"      </i>",
"      ,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2001, 33(4):473-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/20/6469/abstract-text/11462182/pubmed\" id=\"11462182\" target=\"_blank\">",
"        11462182",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Donovan CA, Fan-Havard P, Tecson-Tumang FT, et al, &ldquo;Enteric Eradication of Vancomycin-Resistant",
"      <i>",
"       Enterococcus faecium",
"      </i>",
"      With Oral Bacitracin,&rdquo;",
"      <i>",
"       Diagn Microbiol Infect Dis",
"      </i>",
"      , 1994, 18(2):105-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/20/6469/abstract-text/8062527/pubmed\" id=\"8062527\" target=\"_blank\">",
"        8062527",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vale MA, Connolly A, Epstein AM, et al, &ldquo;Bacitracin-Induced Anaphylaxis,&rdquo;",
"      <i>",
"       Arch Dermatol",
"      </i>",
"      , 1978, 114(5):800.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Westerman EL, &ldquo;Toxicity of Mediastinal Irrigation With Bacitracin,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1983, 250(7):899.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Young GP, Ward PB, Bayley N, et al, &ldquo;Antibiotic-Associated Colitis Due to",
"      <i>",
"       Clostridium difficile",
"      </i>",
"      : Double-Blind Comparison of Vancomycin With Bacitracin,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 1985, 89(5):1038-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/20/6469/abstract-text/4043661/pubmed\" id=\"4043661\" target=\"_blank\">",
"        4043661",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9052 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-5368725AE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_20_6469=[""].join("\n");
var outline_f6_20_6469=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708645\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138673\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138674\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138695\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138676\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138688\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138677\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138653\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138638\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138656\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138654\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138692\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138702\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138693\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138660\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138642\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298807\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138647\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6140224\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6140235\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138663\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138651\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138664\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138641\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138659\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9052\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9052|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/56/1925?source=related_link\">",
"      Bacitracin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/63/33779?source=related_link\">",
"      Bacitracin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_20_6470="Maintenance fluid therapy in children";
var content_f6_20_6470=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Maintenance fluid therapy in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/20/6470/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/20/6470/contributors\">",
"     Michael J Somers, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/20/6470/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/20/6470/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/20/6470/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/20/6470/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/20/6470/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluid therapy preserves the normal volume and composition of body fluids and, if needed, corrects any existing abnormalities. In children, the most common clinical abnormality requiring fluid therapy is hypovolemia, primarily due to vomiting and diarrhea from gastroenteritis.",
"   </p>",
"   <p>",
"    Thus, it is clinically useful to divide fluid therapy into two potential components: provision of volume for homeostatic needs (maintenance therapy), and provision of fluid for deficit requirements (repletion therapy).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maintenance therapy replaces the ongoing losses of water and electrolytes occurring via normal physiologic processes.",
"     </li>",
"     <li>",
"      Repletion therapy replaces the water and electrolyte deficits that have accrued via some perturbation in normal processes. Repletion returns the patient to a normal volume and electrolyte status. Thus, in a patient who is hypovolemic, fluid therapy will include both repletion and maintenance therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Maintenance fluid therapy, including alterations in maintenance requirements, will be reviewed here. Assessment of hypovolemia and treatment of dehydration are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3607?source=see_link\">",
"     \"Clinical assessment and diagnosis of hypovolemia (dehydration) in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=see_link\">",
"     \"Treatment of hypovolemia (dehydration) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MAINTENANCE WATER NEEDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Daily water needs are based upon insensible losses from the respiratory tract and skin, and sensible losses from urine and stool [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6470/abstract/1\">",
"     1",
"    </a>",
"    ]. Water requirements are estimated in direct relation to caloric energy expenditures, with approximately 100 mL of exogenous water needed for every 100",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    of energy expended.",
"   </p>",
"   <p>",
"    The most widely utilized method for calculation of water needs is based upon the estimated caloric expenditures of hospitalized children at bed rest [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6470/abstract/2\">",
"     2",
"    </a>",
"    ]. Caloric expenditure varies directly with body weight, with the rate changing over three broad weight ranges.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Weight less than 10 kg &mdash; 100",
"      <span class=\"nowrap\">",
"       kcal/kg",
"      </span>",
"     </li>",
"     <li>",
"      Weight from 10 to 20 kg &mdash; 1000 kcal for first 10 kg of body weight plus 50",
"      <span class=\"nowrap\">",
"       kcal/kg",
"      </span>",
"      for any increment of weight above 10 kg",
"     </li>",
"     <li>",
"      Weight from 20 to 80 kg &mdash; 1500 kcal for first 20 kg of body weight plus 20",
"      <span class=\"nowrap\">",
"       kcal/kg",
"      </span>",
"      for any increment of weight above 20 kg.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Calculation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above caloric groupings are directly applied to determine water maintenance requirements. Two methods of calculation are currently popular, one based upon a volume calculated for needs over 24 hours, and the other upon a volume that would be delivered on an hourly basis.",
"   </p>",
"   <p>",
"    Both methods assume that urinary losses are isosmotic to plasma. Since the kidney can both concentrate and dilute the urine, normal children generally tolerate fluid intakes below or above these calculated values, but these calculations serve as a starting point for a presumptive maintenance fluid volume.",
"   </p>",
"   <p>",
"    At body weights above 80 kg, the water requirement based upon total body weight falls, so these methods would significantly overestimate the fluid requirements in individuals whose body weight exceeds 80 kg. In these individuals, total maintenance needs are generally capped at 2.4 liters daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Method 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance fluid volume for a 24-hour period (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?7/60/8129?source=see_link\">",
"     calculator 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Weight less than 10 kg &mdash; 100",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"     </li>",
"     <li>",
"      Weight &gt;10 kg to 20 kg &mdash; 1000 mL for first 10 kg of body weight plus 50",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      for any increment of weight over 10 kg",
"     </li>",
"     <li>",
"      Weight &gt;20 kg to 80 kg &mdash; 1500 mL for first 20 kg of body weight plus 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      for any increment of weight over 20 kg, up to a maximum of 2400 mL daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Method 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance fluid needed on an hourly basis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Weight less than 10 kg &mdash; 4",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour",
"     </li>",
"     <li>",
"      Weight &gt;10 kg to 20 kg &mdash; 40",
"      <span class=\"nowrap\">",
"       mL/hour",
"      </span>",
"      for first 10 kg of body weight plus 2",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour for any increment of weight over 10 kg",
"     </li>",
"     <li>",
"      Weight &gt;20 kg to 80 kg &mdash; 60",
"      <span class=\"nowrap\">",
"       mL/hour",
"      </span>",
"      for first 20 kg of body weight plus 1",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour for any increment of weight over 20 kg, to a maximum of 100",
"      <span class=\"nowrap\">",
"       mL/hour,",
"      </span>",
"      up to a maximum of 2400 mL daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Comparison between methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;The total daily volume of fluid prescribed by the hourly format is a bit lower than the daily format, but the difference is almost always of no clinical significance. For example, the maintenance needs for a 12-kg child are calculated using both methods:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Utilizing the 24-hour method, the maintenance needs would be 1100 mL for 24 hours (1000 mL for the first 10 kg, plus 100 mL for the next 2 kg [50",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per day for each kg of body weight between 10 and 20 kg]).",
"     </li>",
"     <li>",
"      Utilizing the hourly method, the maintenance needs would be slightly lower at 44 mL per hour or 1056 mL for 24 hours (40",
"      <span class=\"nowrap\">",
"       mL/hour",
"      </span>",
"      for the first 10 kg of body weight, plus 4",
"      <span class=\"nowrap\">",
"       mL/hour",
"      </span>",
"      for the next 2 kg [2",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour for each kg of body weight between 10 and 20 kg]).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Sensible and insensible water loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, daily water needs are based upon insensible losses from the respiratory tract and from the skin, and sensible water losses in urine and stool output [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6470/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Under normal physiological conditions, insensible losses account for approximately 45 mL per 100 kcal of energy expended. In patients greater than 10 kg, the insensible needs are calculated based upon body surface area at a rate of about 300 to 400",
"    <span class=\"nowrap\">",
"     mL/M2.",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Skin losses, due to evaporation from convection and conduction, account for two-thirds of the insensible losses (30 mL per 100 kcal), and increase with higher core body temperature",
"     </li>",
"     <li>",
"      Respiratory losses account for one-third of insensible losses (15 mL per 100 kcal), and result from the warming and humidification of inspired air",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since water loss from stool is negligible in healthy children, sensible water losses are primarily due to the daily urine output (55 mL per 100 kcal). An obligate urine water loss is required to excrete the daily solute load that ensues from dietary intake and cellular metabolism. The daily water maintenance requirements, as calculated above, assume a normal and age-appropriate dietary solute load, and urine that is isosmotic to plasma (approximately 290",
"    <span class=\"nowrap\">",
"     mosmol/L).",
"    </span>",
"    The minimal obligate urine volume is 25 mL for every 100 kcal of energy expended and requires maximal stimulation of antidiuretic hormone (ADH) release, with a urine osmolality that can reach 1200 to 1400",
"    <span class=\"nowrap\">",
"     mosmol/L.",
"    </span>",
"   </p>",
"   <p>",
"    Thus, individuals who do not receive their calculated maintenance water therapy, or who have increased losses, can still maintain water balance by limiting urinary water loss via increased release of ADH, and increased fluid intake because of osmoreceptor stimulation. In these settings, ADH release is stimulated by initial negative water balance, which raises the plasma osmolality and, thereby, triggers osmoreceptors (",
"    <a class=\"graphic graphic_figure graphicRef65195 \" href=\"UTD.htm?14/61/15325\">",
"     figure 1",
"    </a>",
"    ). Persistent water deprivation may also trigger baroreceptors that sense changes in intravascular or atrial stretch as effective intravascular volume falls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Variability in maintenance water needs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insensible or sensible water losses can vary with a number of clinical scenarios, often as a function of fluid intake, physical exertion, and complicating disease states (",
"    <a class=\"graphic graphic_table graphicRef72500 \" href=\"UTD.htm?25/3/25659\">",
"     table 1",
"    </a>",
"    ). As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Premature infants have increased insensible water losses from the skin due to an increased surface area for mass and a thinner dermis. Water losses are accentuated if the infant is cared for in an open radiant heater or is receiving phototherapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27591?source=see_link\">",
"       \"Fluid and electrolyte therapy in newborns\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with a colostomy or ileostomy will have increased stool water losses due to their inability to reabsorb intestinal fluid that is usually presented to more distal regions of the digestive tract.",
"     </li>",
"     <li>",
"      Patients with oliguric renal failure will have decreased urinary water losses and are at risk for volume overload if maintenance fluid is not modified.",
"     </li>",
"     <li>",
"      Patients on ventilators with prehumidified air will have decreased water losses that normally occur with respiration.",
"     </li>",
"     <li>",
"      Patients with burns will have increased insensible water and electrolyte losses.",
"     </li>",
"     <li>",
"      Patients with fever will also have increased insensible water and electrolyte losses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In such patients, the daily fluid intake must be appropriately adjusted to maintain balance. Unreplaced water losses will lead to both hypernatremia and volume depletion, while water intake in excess of excretory capacity will lead to both hyponatremia and volume expansion.",
"   </p>",
"   <p>",
"    When prescribing fluid therapy, the clinician always should consider net volume balance as a dynamic interplay between input and output (ie, an accounting ledger of gains and losses). Often, clinicians may focus on specific parameters, such as urine flow, with a common misperception that urine output exceeding 0.5 to 1",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour corresponds to good renal output. However, the appropriateness of any urine volume over any unit of time directly corresponds to the patient's volume and solute balance, and the concomitant exogenous provision or loss of fluid or solute. Thus, a large volume of fluid in a normovolemic patient should normally lead to a large volume diuresis. In contrast, the hypovolemic patient given a similar large volume of fluid should have limited output until the volume depletion is corrected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MAINTENANCE ELECTROLYTE NEEDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance electrolyte requirements, like water requirements, are estimated based upon caloric energy expenditure. In children, the daily requirements are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sodium and chloride &mdash; 2 to 3",
"      <span class=\"nowrap\">",
"       mEq/100",
"      </span>",
"      mL of water per day",
"     </li>",
"     <li>",
"      Potassium &mdash; 1 to 2",
"      <span class=\"nowrap\">",
"       mEq/100",
"      </span>",
"      mL of water per day",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Urinary electrolyte losses account for the majority of maintenance electrolyte needs, with fewer electrolyte losses normally coming from losses in sweat and stool. As is the case with water balance, the maintenance electrolyte intake must be considered within the specific clinical context, especially when an abnormal physiologic condition is ongoing. For example, sodium and potassium intake may need to be reduced in patients with oliguric renal failure to prevent volume expansion and hyperkalemia; conversely, their intake may need to be increased in patients with diarrhea or burns to prevent volume depletion and hypokalemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MAINTENANCE PARENTERAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on the above estimations, the standard commercially available parenteral solution of one-quarter isotonic or normal saline with 20",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    potassium will meet the usual electrolyte maintenance needs of a healthy, normovolemic child when a maintenance volume of fluid is administered. The above solution is often given along with 5 percent dextrose, which provides approximately 20 percent of daily caloric needs assuming a maintenance fluid rate.",
"   </p>",
"   <p>",
"    In a 15-kg child, for example, maintenance water intake is approximately 1250",
"    <span class=\"nowrap\">",
"     mL/day",
"    </span>",
"    (100",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    for the first 10 kg [1000 mL] plus 50",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    for the remaining 5 kg [250 mL]). This volume of one-quarter isotonic saline with 20",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    of potassium will provide:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sodium intake of 47",
"      <span class=\"nowrap\">",
"       mEq/day",
"      </span>",
"      (3.1",
"      <span class=\"nowrap\">",
"       mEq/kg)",
"      </span>",
"     </li>",
"     <li>",
"      Potassium intake of 25",
"      <span class=\"nowrap\">",
"       mEq/day",
"      </span>",
"      (1.67",
"      <span class=\"nowrap\">",
"       mEq/kg)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hospitalized children",
"    </span>",
"    &nbsp;&mdash;&nbsp;In hospitalized patients, the ongoing administration of hypotonic maintenance fluids may result in hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6470/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. Hyponatremia is typically caused by the intake of water that cannot be excreted due primarily to persistent antidiuretic hormone (ADH) secretion, which occurs in two settings: volume depletion, and the syndrome of inappropriate ADH stimulation (SIADH) in euvolemic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6470/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link\">",
"     \"Causes of hyponatremia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=see_link\">",
"     \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children, SIADH can occur in the following clinical situations [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6470/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Surgery",
"     </li>",
"     <li>",
"      Central nervous system disease, including infection, trauma, or hemorrhage",
"     </li>",
"     <li>",
"      Pulmonary disease, particularly pneumonia and respiratory syncytial virus bronchiolitis [",
"      <a class=\"abstract\" href=\"UTD.htm?6/20/6470/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Drugs that enhance ADH release or effect (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/36/5706?source=see_link\">",
"       carbamazepine",
"      </a>",
"      and high-dose intravenous",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Response to pain or anxiety",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The effects of fluid management, including the potential role of nonosmotic ADH stimulation on plasma sodium, were evaluated in a study of hospitalized children who were admitted for surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6470/abstract/11\">",
"     11",
"    </a>",
"    ]. In this trial, 124 children were randomly assigned to one of four groups based on the tonicity (normal saline [NS] or one-half NS) and rate of administration (100 or 50 percent maintenance rates) of intravenous fluids after surgery. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mean ADH concentrations increased two- to four-fold during the operation and remained elevated through the first 24 hours postoperatively in all four groups.",
"     </li>",
"     <li>",
"      Clinical evidence of hypovolemia was noted in 23 percent of children assigned to 50 percent maintenance fluid. Seven of these 14 patients received NS, and seven one-half NS. There were no cases of hypovolemia in the two groups that received 100 percent maintenance fluid.",
"     </li>",
"     <li>",
"      Hyponatremia (plasma sodium &lt;135",
"      <span class=\"nowrap\">",
"       mEq/L)",
"      </span>",
"      was more common eight hours after surgery in the one-half NS group compared with the NS group (30 versus 10 percent). By 24 hours, following surgery, the difference in the rate of hyponatremia between the groups was smaller and no longer significant (14 versus 8 percent).",
"     </li>",
"     <li>",
"      Increases in plasma sodium of at least 5",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      were noted in 7 of 62 (11 percent) patients treated with NS, but in none of the patients who received one-half NS. Three patients developed a plasma sodium &gt;145",
"      <span class=\"nowrap\">",
"       mEq/L,",
"      </span>",
"      all of whom received NS at 50 percent maintenance.",
"     </li>",
"     <li>",
"      In the patients who received NS at 100 percent maintenance, there was a fall in mean plasma sodium from 138 to 136",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      in association with an increase in urine osmolality during the 24 hours following surgery.",
"     </li>",
"     <li>",
"      Fluid therapy was modified in 16 of the 124 children eight hours after surgery. The reason for modification was hypovolemia in 14 patients, all of whom received 50 percent maintenance fluid; and hyponatremia in two patients who received NS at 100 percent maintenance rate and fulfilled criteria for SIADH.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other trials have also demonstrated an increase risk of hyponatremia in postoperative children randomly assigned to hypotonic solution compared with those who received isotonic solution [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6470/abstract/6,12\">",
"     6,12",
"    </a>",
"    ]. In both studies, patients had elevated levels of ADH.",
"   </p>",
"   <p>",
"    Results from these two studies in postoperative children support the contributory role of nonosmotic ADH secretion for decreasing plasma sodium because of the inability to excrete free water. In addition, fluid restriction to 50 percent in the first study resulted in hypovolemia in a significant portion of patients. These studies underscore the need for assessment of the patient's clinical condition and volume status before and during parenteral fluid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6470/abstract/13\">",
"     13",
"    </a>",
"    ]. For children who are thought to be volume depleted, initial therapy is directed at repletion of the estimated deficit with an isotonic solution [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6470/abstract/8\">",
"     8",
"    </a>",
"    ]. Volume repletion will also remove any hypovolemia-induced stimulus to ADH release, thereby improving the ability to excrete free water.",
"   </p>",
"   <p>",
"    Once the patient is thought to be euvolemic, parental fluid therapy must be chosen with consideration of the patient's ability to excrete free water. In hospitalized children, there is a high likelihood of SIADH due to a variety of disease states, surgery, pain, or anxiety, and in these patients, isotonic solution is preferable to the use of a hypotonic solution.",
"   </p>",
"   <p>",
"    Based upon limited data, it is reasonable to begin at 100 percent maintenance rates with isotonic fluid in hospitalized children, and readjust both the rate and tonicity of therapy based upon ongoing and frequent clinical assessment of the child's fluid and electrolyte status [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6470/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A detailed discussion of the clinical manifestations, assessment, and treatment of volume depletion in children is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3607?source=see_link\">",
"     \"Clinical assessment and diagnosis of hypovolemia (dehydration) in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=see_link\">",
"     \"Treatment of hypovolemia (dehydration) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance fluid therapy replaces the ongoing losses of water and electrolytes occurring via normal physiologic processes. These losses are based upon insensible losses from the respiratory tract and skin, and sensible losses from urine and stool.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Water requirements are estimated in direct relation to caloric energy expenditures and vary directly with body weight. In children, these specific water requirements change over three broad weight ranges. Two methods based upon the child's weight are generally used by clinicians to calculate maintenance water (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?7/60/8129?source=see_link\">",
"       calculator 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Maintenance water needs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Water maintenance needs can vary with physical exertion and clinical conditions that alter either insensible or sensible water losses (",
"      <a class=\"graphic graphic_table graphicRef72500 \" href=\"UTD.htm?25/3/25659\">",
"       table 1",
"      </a>",
"      ). These include prematurity, a colostomy or ileostomy, oliguric renal failure, the need for mechanical ventilation, or syndrome of inappropriate antidiuretic hormone (SIADH), (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Variability in maintenance water needs'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Hospitalized children'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Electrolyte maintenance based upon caloric energy expenditures include sodium and chloride requirements of 2 to 3",
"      <span class=\"nowrap\">",
"       mEq/100",
"      </span>",
"      mL of water, and potassium requirements of 1 to 2",
"      <span class=\"nowrap\">",
"       mEq/100",
"      </span>",
"      mL of water. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Maintenance electrolyte needs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In hospitalized euvolemic children who are dependent upon parenteral fluid therapy, the rate and tonicity of fluids must be chosen with careful consideration of the patient's ability to excrete free water. Nonosmotic ADH secretion due to a variety of disease states, pain, or anxiety is common in hospitalized children. In these patients, we suggest the use of isotonic fluid and frequent assessment to prevent or treat hyponatremia (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Hospitalized children'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3349166\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Erin Endom, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6470/abstract/1\">",
"      Hellerstein S. Fluid and electrolytes: clinical aspects. Pediatr Rev 1993; 14:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6470/abstract/2\">",
"      HOLLIDAY MA, SEGAR WE. The maintenance need for water in parenteral fluid therapy. Pediatrics 1957; 19:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6470/abstract/3\">",
"      Moritz ML, Ayus JC. Prevention of hospital-acquired hyponatremia: a case for using isotonic saline. Pediatrics 2003; 111:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6470/abstract/4\">",
"      Duke T, Molyneux EM. Intravenous fluids for seriously ill children: time to reconsider. Lancet 2003; 362:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6470/abstract/5\">",
"      Choong K, Kho ME, Menon K, Bohn D. Hypotonic versus isotonic saline in hospitalised children: a systematic review. Arch Dis Child 2006; 91:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6470/abstract/6\">",
"      Choong K, Arora S, Cheng J, et al. Hypotonic versus isotonic maintenance fluids after surgery for children: a randomized controlled trial. Pediatrics 2011; 128:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6470/abstract/7\">",
"      Holliday MA, Friedman AL, Segar WE, et al. Acute hospital-induced hyponatremia in children: a physiologic approach. J Pediatr 2004; 145:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6470/abstract/8\">",
"      Friedman AL, Ray PE. Maintenance fluid therapy: what it is and what it is not. Pediatr Nephrol 2008; 23:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6470/abstract/9\">",
"      Gerigk M, Gnehm HE, Rascher W. Arginine vasopressin and renin in acutely ill children: implication for fluid therapy. Acta Paediatr 1996; 85:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6470/abstract/10\">",
"      Hanna S, Tibby SM, Durward A, Murdoch IA. Incidence of hyponatraemia and hyponatraemic seizures in severe respiratory syncytial virus bronchiolitis. Acta Paediatr 2003; 92:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6470/abstract/11\">",
"      Neville KA, Sandeman DJ, Rubinstein A, et al. Prevention of hyponatremia during maintenance intravenous fluid administration: a prospective randomized study of fluid type versus fluid rate. J Pediatr 2010; 156:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6470/abstract/12\">",
"      Coulthard MG, Long DA, Ullman AJ, Ware RS. A randomised controlled trial of Hartmann's solution versus half normal saline in postoperative paediatric spinal instrumentation and craniotomy patients. Arch Dis Child 2012; 97:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6470/abstract/13\">",
"      Holliday MA, Ray PE, Friedman AL. Fluid therapy for children: facts, fashions and questions. Arch Dis Child 2007; 92:546.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6122 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-210.101.131.232-2A3F076F4F-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_20_6470=[""].join("\n");
var outline_f6_20_6470=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MAINTENANCE WATER NEEDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Calculation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Method 1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Method 2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Comparison between methods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Sensible and insensible water loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Variability in maintenance water needs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MAINTENANCE ELECTROLYTE NEEDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MAINTENANCE PARENTERAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hospitalized children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3349166\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6122\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6122|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/61/15325\" title=\"figure 1\">",
"      Osmoregulation of ADH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6122|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/3/25659\" title=\"table 1\">",
"      Factors water maintenance needs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?7/60/8129?source=related_link\" title=\"calculator 1\">",
"      Calculator: Maintenance fluid calculation for children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=related_link\">",
"      Causes of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3607?source=related_link\">",
"      Clinical assessment and diagnosis of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27591?source=related_link\">",
"      Fluid and electrolyte therapy in newborns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=related_link\">",
"      Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=related_link\">",
"      Treatment of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_20_6471="Fosaprepitant (intravenous aprepitant): Drug information";
var content_f6_20_6471=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fosaprepitant (intravenous aprepitant): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/55/6004?source=see_link\">",
"    see \"Fosaprepitant (intravenous aprepitant): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/40/2695?source=see_link\">",
"    see \"Fosaprepitant (intravenous aprepitant): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5634805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Emend&reg; for Injection",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F12822224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Emend&reg; IV",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F5657517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiemetic;",
"     </li>",
"     <li>",
"      Substance P/Neurokinin 1 Receptor antagonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F5657638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Prevention of chemotherapy-induced nausea/vomiting:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Single-dose regimen for highly-emetogenic chemotherapy:",
"     </i>",
"     150 mg ~30 minutes prior to chemotherapy on day 1 only (in combination with a 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     antagonist on day 1 and dexamethasone on days 1 to 4)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Single-dose regimen for moderately-emetogenic chemotherapy:",
"     </i>",
"     150 mg ~30 minutes prior to chemotherapy on day 1 only (in combination with a 5-HT3 antagonist and dexamethasone on day 1, and either a 5-HT3 antagonist or dexamethasone on days 2 and 3) (NCCN Antiemesis guidelines v.1.2013)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F5657639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F5657640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild, moderate, or severe impairment: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dialysis-dependent end-stage renal disease (ESRD): No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F5657641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;\">",
"     Mild or moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;\">",
"     Severe impairment (Child-Pugh class C): Has not been evaluated; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F5657664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Emend&reg; for Injection: 115 mg [DSC] [contains edetate disodium, lactose 287.5 mg, polysorbate 80]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Emend&reg; for Injection: 150 mg [contains edetate disodium, lactose 375 mg, polysorbate 80]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F5657515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5657642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     150 mg: Infuse over 20-30 minutes ~30 minutes prior to chemotherapy",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F5657554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in sodium chloride 0.9%;",
"     <b>",
"      incompatible",
"     </b>",
"     with solutions containing calcium (eg, lactated Ringer&rsquo;s solution, Hartmann&rsquo;s solution) or magnesium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Incompatible:",
"     </b>",
"     Dexamethasone sodium phosphate, palonosetron.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Granisetron, methylprednisolone sodium succinate, ondansetron.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F5657519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of acute and delayed nausea and vomiting associated with moderately- and highly-emetogenic chemotherapy (in combination with other antiemetics)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5657514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Fosaprepitant may be confused with aprepitant, fosamprenavir, fospropofol",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Emend&reg; for Injection (fosaprepitant) may be confused with Emend&reg; (aprepitant) which is an oral capsule formulation.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F5657529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse reactions reported with aprepitant and fosaprepitant (as part of a combination chemotherapy regimen) occurring at a higher frequency than standard antiemetic therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (1% to 3%), headache (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia (2%), constipation 2%), dyspepsia (2%), diarrhea (1%), eructation (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased (1% to 3%), AST increased (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reactions (3%; includes erythema, induration, pain, pruritus, or thrombophlebitis)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Hiccups (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abdominal pain, alkaline phosphatase increased, anaphylactic reaction, anemia, angioedema, bradycardia, candidiasis, cardiovascular disorder, chest discomfort, chills, cognitive disorder, conjunctivitis, cough, disorientation, dizziness, duodenal ulcer (perforating), dyspnea, edema, erythema, flushing, gait disturbance, hematuria (microscopic), hyperglycemia, hyperhydrosis, hypersensitivity reaction, hypertension, hyponatremia, miosis, nausea, neutropenia, neutropenic colitis, neutropenic fever, palpitation, photosensitivity, pollakiuria, polyuria, pruritus, rash, sensory disturbance, somnolence, staphylococcal infection, Stevens-Johnson syndrome, stomatitis, subileus, tinnitus, toxic epidermal necrolysis, urticaria, visual acuity decreased, vomiting, wheezing",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5657524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fosaprepitant, aprepitant, polysorbate 80, or any component of the formulation; concurrent use with pimozide or cisapride",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Concurrent use with astemizole or terfenadine",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5657525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity: Immediate hypersensitivity has been reported (rarely) with fosaprepitant. Stop infusion with hypersensitivity symptoms (dyspnea, erythema, flushing, or anaphylaxis); do not reinitiate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; has not been studied in patients with severe hepatic impairment (Child-Pugh class C).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nausea/vomiting: Not studied for treatment of existing nausea and vomiting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug interactions: Fosaprepitant is rapidly converted to aprepitant, which has a high potential for drug interactions. Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Chronic continuous administration is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Excipient: Contains polysorbate 80, which is associated with hypersensitivity reactions.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F5657546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C19 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak), CYP2C9 (weak), CYP3A4 (moderate);",
"     <b>",
"      Induces",
"     </b>",
"     CYP2C9 (weak/moderate), CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5657545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May increase the serum concentration of Fosaprepitant. Specifically, concentrations of aprepitant are likely to be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Astemizole: Fosaprepitant may increase the serum concentration of Astemizole. The active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Fosaprepitant may increase the serum concentration of Benzodiazepines (metabolized by oxidation). Specifically, the active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Fosaprepitant may increase the serum concentration of Cisapride. The active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Fosaprepitant may decrease the serum concentration of Contraceptives (Estrogens). The active metabolite aprepitant is likely responsible for this effect.  Management: Alternative or additional methods of contraception should be used both during treatment with fosaprepitant or aprepitant and for at least one month following the last fosaprepitant/aprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Fosaprepitant may decrease the serum concentration of Contraceptives (Progestins). The active metabolite aprepitant is likely responsible for this effect.  Management: Alternative or additional methods of contraception should be used both during treatment with aprepitant or fosaprepitant and for at least one month following the last aprepitant/fosaprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Fosaprepitant may increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diltiazem: May increase the serum concentration of Fosaprepitant. Specifically, diltiazem may increase the concentration of the active metabolite aprepitant. Fosaprepitant may increase the serum concentration of Diltiazem. The active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: When used concomitantly with moderate inhibitors of CYP3A4, eplerenone dosing recommendations may vary depending on international labeling. Consult appropriate labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine.  Management: In patients with a resting heart rate over 60 beats per minute receiving a moderate CYP3A4 inhibitor, ivabradine initiation at an adult dose of 2.5 mg twice daily may be considered.  Monitor heart rate closely under these circumstances.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: U.S. labeling: start at 20 mg/day and limit to max of 80 mg/day with moderate CYP3A4 inhibitor.  Canadian labeling: limit to max of 40 mg/day with moderate CYP3A4 inhibitor; avoid concomitant use of grapefruit products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PARoxetine: May decrease serum concentrations of the active metabolite(s) of Fosaprepitant. Fosaprepitant may decrease the serum concentration of PARoxetine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Fosaprepitant may increase the serum concentration of Pimozide. The active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine adult dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Fosaprepitant. More specifically, rifampin may decrease concentrations of the active metabolite aprepitant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Terfenadine: Fosaprepitant may increase the serum concentration of Terfenadine. The active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TOLBUTamide: Fosaprepitant may decrease the serum concentration of TOLBUTamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Fosaprepitant may decrease the serum concentration of Warfarin. The active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F5657549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Aprepitant serum concentration may be increased when taken with grapefruit juice; avoid concurrent use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid St John's wort (may decrease aprepitant levels).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F5657520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5657521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies for aprepitant. Use during pregnancy only if clearly needed. Efficacy of hormonal contraceptive may be reduced; alternative or additional methods of contraception should be used both during treatment with fosaprepitant or aprepitant and for at least 1 month following the last fosaprepitant/aprepitant dose.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5657523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16135734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if fosaprepitant is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F6255767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Emend Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (1): $308.35",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F11390215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Emend IV (AU, IL, NZ, SG);",
"     </li>",
"     <li>",
"      Ivemend (CH, CZ, DE, DK, EE, FR, GB, GR, IE, NL, NO, PT, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F5657626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fosaprepitant is a prodrug of aprepitant, a substance P/neurokinin 1 (NK1) receptor antagonist. It is rapidly converted to aprepitant which prevents acute and delayed vomiting by inhibiting the substance P/neurokinin 1 (NK1) receptor; augments the antiemetic activity of the 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     receptor antagonist and corticosteroid activity and inhibits chemotherapy-induced emesis.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F5657628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Fosaprepitant: ~5 L; Aprepitant: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~70 L; crosses the blood-brain barrier",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: Aprepitant: &gt;95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Fosaprepitant: Hepatic and extrahepatic; rapidly (within 30 minutes after the end of infusion) converted to aprepitant (nearly complete conversion)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Aprepitant: Hepatic via CYP3A4 (major); CYP1A2 and CYP2C19 (minor); forms 7 weakly-active metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Fosaprepitant: ~2 minutes; Aprepitant: ~9-13 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: Fosaprepitant is converted to aprepitant within 30 minutes after the end of infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (57%); feces (45%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Basch E, Prestrud AA, Hesketh PJ, et al, \"Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(31):4189-98.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/20/6471/abstract-text/21947834/pubmed\" id=\"21947834\" target=\"_blank\">",
"        21947834",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cocquyt V, Van Belle S, Reinhardt RR, et al, &ldquo;Comparison of L-758,298, a Prodrug for the Selective Neurokinin-1 Antagonist, L-754,030, With Ondansetron for the Prevention of Cisplatin-Induced Emesis,&rdquo;",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 2001, 37(7):835-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/20/6471/abstract-text/11313170/pubmed\" id=\"11313170\" target=\"_blank\">",
"        11313170",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grunberg S, Chua D, Maru A, et al, &ldquo;Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol -- EASE,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(11):1495-501.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/20/6471/abstract-text/21383291/pubmed\" id=\"21383291\" target=\"_blank\">",
"        21383291",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lasseter KC, Gambelle J, Jin B, et al, &ldquo;Tolerability of Fosaprepitant and Bioequivalency to Aprepitant in Healthy Subjects,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2007,47(7):834-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/20/6471/abstract-text/117525168/pubmed\" id=\"117525168\" target=\"_blank\">",
"        117525168",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marbury TC, Jin B, Panebianco D, et al, &ldquo;Lack of Effect of Aprepitant or its Prodrug Fosaprepitant on QTc Intervals in Healthy Subjects,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2009, 109(2):418-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/20/6471/abstract-text/19608812/pubmed\" id=\"19608812\" target=\"_blank\">",
"        19608812",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marbury TC, Ngo PL, Shadle CR, et al, &ldquo;Pharmacokinetics of Oral Dexamethasone and Midazolam When Administered With Single-Dose Intravenous 150 mg Fosaprepitant in Healthy Adult Subjects,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2011, 51(12):1712-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/20/6471/abstract-text/21209230/pubmed\" id=\"21209230\" target=\"_blank\">",
"        21209230",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Multinational Association of Supportive Care in Cancer, MASCC/ESMO &ldquo;Antiemetic Guideline 2011,&rdquo; Updated April 2011. Available at  file://www.mascc.org/assets/documents/MASCC_Guidelines_English_2011.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Antiemesis,&rdquo; Version 1.2013. Available at  file://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Belle S, Lichinitser SR, Navari RM, et al,&rdquo; Prevention of Cisplatin-Induced Acute and Delayed Emesis by the Selective Neurokinin-1 Antagonists, L-758,298 and MK-869,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2002, 94(11):3032-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/20/6471/abstract-text/12115394/pubmed\" id=\"12115394\" target=\"_blank\">",
"        12115394",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9032 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-23F828356C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_20_6471=[""].join("\n");
var outline_f6_20_6471=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5634805\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12822224\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5657517\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5657638\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5657639\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5657640\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5657641\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5657664\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5657515\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5657642\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5657554\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5657519\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5657514\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5657529\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5657524\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5657525\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5657546\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5657545\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5657549\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5657520\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5657521\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5657523\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16135734\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6255767\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390215\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5657626\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5657628\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9032\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9032|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/55/6004?source=related_link\">",
"      Fosaprepitant (intravenous aprepitant): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/40/2695?source=related_link\">",
"      Fosaprepitant (intravenous aprepitant): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_20_6472="Pimozide: Drug information";
var content_f6_20_6472=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pimozide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/48/4869?source=see_link\">",
"    see \"Pimozide: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/22/34151?source=see_link\">",
"    see \"Pimozide: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F7290571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F209993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Orap&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F209994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Pimozide&reg;;",
"     </li>",
"     <li>",
"      Orap&reg;;",
"     </li>",
"     <li>",
"      PMS-Pimozide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F210031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antipsychotic Agent, Typical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F209997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tourette's disorder:",
"     </b>",
"     Oral: Initial: 1-2 mg/day in divided doses, then increase dosage as needed every other day; maximum dose: 10 mg/day or 0.2 mg/kg/day (whichever is less);",
"     <b>",
"      Note:",
"     </b>",
"     If therapy requires exceeding dose of 4 mg/day, CYP2D6 geno-/phenotyping should be performed; CYP2D6 poor metabolizers should be dose titrated in &ge;14-day increments and should not receive doses in excess of 4 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     An ECG should be performed baseline and periodically thereafter, especially during dosage adjustment.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F210014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/22/34151?source=see_link\">",
"      see \"Pimozide: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tourette's disorder:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children 2-12 years:",
"     </i>",
"     Initial: 0.05 mg/kg preferably once at bedtime; may be increased every third day to a maximum of 0.2 mg/kg/day (do not exceed 10 mg/day); usual range: 2-4 mg/day.",
"     <b>",
"      Note:",
"     </b>",
"     If therapy requires exceeding dose of 0.05 mg/kg/day, CYP2D6 geno-/phenotyping should be performed; CYP2D6 poor metabolizers should be dose titrated in &ge;14-day increments and should not receive doses in excess of 0.05 mg/kg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children &gt;12 years:",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     An ECG should be performed baseline and periodically thereafter, especially during dosage adjustment.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F209998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommend initial dose of 1 mg/day; periodically attempt gradual reduction of dose to determine if tic persists; follow up for 1-2 weeks before concluding the tic is a persistent disease phenomenon and not a manifestation of drug withdrawal.",
"     <b>",
"      Note:",
"     </b>",
"     An ECG should be performed baseline and periodically thereafter, especially during dosage adjustment.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F7883543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      ECG changes:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation &gt;0.47 seconds or &gt;25% above baseline: Decrease dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation &gt;0.52 seconds or &gt;25% above baseline: Decrease dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      NMS syndrome:",
"     </b>",
"     Discontinue (monitor carefully if  therapy is reinitiated).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tardive dyskinesia signs/symptoms:",
"     </b>",
"     Consider discontinuing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F209972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orap&reg;: 1 mg, 2 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F209957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F209975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Suppression of severe motor and phonic tics in patients with Tourette's disorder who have failed to respond satisfactorily to standard treatment",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F210028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Psychosis; reported use in individuals with delusions focused on physical symptoms (ie, preoccupation with parasitic infestation); Huntington's chorea",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14100513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F210029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Frequencies as reported in adults (limited data) and/or children with Tourette's disorder:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Sedation (70%), akathisia (40%), akinesia (40%), drowsiness (35%), behavior changes (22% to 25%), somnolence (up to 25% in children)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (25%), constipation (20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Impotence (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle tightness (15%), weakness (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Accommodation decreased (20%), visual disturbance (3% to 20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Abnormal ECG (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Depression (10%), insomnia (10%), speech disorder (10%), nervousness (5% to 6%), headache (3% to 5%), dreams abnormal (3%), hyperkinesias (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Salivation increased (6%), appetite increased (5%), diarrhea (5%), taste disturbance (5%), thirst (5%), dysphagia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Rigidity (10%), stooped posture (10%), handwriting change (5%), myalgia (3%), torticollis (3%), tremor (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Photophobia (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Frequency not defined, postmarketing, and/or case reports (some reported  for disorders other than Tourette's disorder):",
"     </b>",
"     Anorexia, blurred vision, cataracts, chest pain, diaphoresis, dizziness, excitement; extrapyramidal symptoms (dystonia, pseudoparkinsonism, tardive dyskinesia); GI distress, gingival hyperplasia (case report), hemolytic anemia, hyper-/hypotension, hyponatremia, libido decreased, nausea, neuroleptic malignant syndrome, orthostatic hypotension, nocturia, palpitation, periorbital edema, polyuria, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, seizure, skin irritation, syncope, tachycardia, ventricular arrhythmia, vomiting, weight gain/loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F209978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pimozide or any component of the formulation; severe toxic CNS depression; coma; history of cardiac arrhythmias; congenital long QT syndrome; concurrent use with QT",
"     <sub>",
"      c",
"     </sub>",
"     -prolonging agents; hypokalemia or hypomagnesemia; concurrent use of drugs that are inhibitors of CYP3A4, including concurrent use of the azole antifungals itraconazole and ketoconazole, macrolide antibiotics (eg, clarithromycin or erythromycin [",
"     <b>",
"      Note:",
"     </b>",
"     The manufacturer lists azithromycin and dirithromycin in its list of contraindicated macrolides; however, azithromycin does not inhibit CYP3A4, but may  interact with pimozide on the basis of QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation]), protease inhibitors (ie, atazanavir, indinavir, nelfinavir, ritonavir, saquinavir), citalopram, escitalopram, nefazodone, sertraline, and other less potent inhibitors of CYP3A4 (eg, fluvoxamine, zileuton); concurrent use with strong CYP2D6 inhibitors (eg, paroxetine); concurrent use with medications that may cause motor or phonic tics (eg, amphetamines, methylphenidate, pemoline) until it is determined if medications or Tourette&rsquo;s is causing tics; treatment of simple tics or tics other than Tourette's",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F209961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered cardiac conduction: May alter cardiac conduction; life-threatening arrhythmias have occurred with therapeutic doses of antipsychotics. Contraindicated in patients with underlying QT prolongation, in those taking medicines that prolong the QT interval, or cause polymorphic ventricular tachycardia; monitor ECG closely for dose-related QT effects. Sudden unexplained deaths have occurred in patients taking high doses (&gt;10 mg). ECG monitoring recommended periodically during therapy. Use caution with concomitant medication or conditions which cause hypokalemia or hypomagnesemia; correct hypokalemia or hypomagnesemia prior to initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, or visual problems. Relative to neuroleptics, pimozide has a moderate potency of cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias: Leukopenia, neutropenia, and agranulocytosis (sometimes fatal) have been reported in clinical trials and postmarketing reports with antipsychotic use; presence of risk factors (eg, pre-existing low WBC or history of drug-induced leuko-/neutropenia) should prompt periodic blood count assessment. Discontinue therapy at first signs of blood dyscrasias or if absolute neutrophil count &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Esophageal dysmotility/aspiration: Antipsychotic use has been associated with esophageal dysmotility and aspiration; use with caution in patients at risk of pneumonia (ie, Alzheimer's disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extrapyramidal symptoms (EPS): May cause extrapyramidal symptoms, including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia. Risk of dystonia (and possibly other EPS) may be greater with increased doses, use of conventional antipsychotics, males, and younger patients. The risk for tardive dyskinesia (may be irreversible) increases with long-term treatment and higher cumulative doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperprolactinemia: Antipsychotics are associated with increased prolactin levels; clinical significance of hyperprolactinemia in patients with breast cancer or other prolactin-dependent tumors is unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuroleptic malignant syndrome (NMS): Use may be associated with NMS; monitor for mental status changes, fever, muscle rigidity, and/or autonomic instability; may also be associated with increased CPK, myogloburia, and acute renal failure. Discontinue use; may recur upon rechallenge.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: May be sedating, use with caution in disorders where CNS depression is a feature; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Temperature regulation: Impaired core body temperature regulation may occur; caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with severe cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dementia:",
"     <b>",
"      [U.S. Boxed Warning]: Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared to placebo.",
"     </b>",
"     Most deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Pimozide is not approved for the treatment of dementia-related psychosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with narrow-angle glaucoma; condition may be exacerbated by cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; condition may be exacerbated by cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parkinson's disease: Use with caution in patients with Parkinson's disease; they may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP2D6 poor metabolizers: Increased pimozide serum concentration and prolonged half-life are observed in CYP2D6 poor metabolizers; dose adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use in patients with dementia is associated with an increased risk of mortality and cerebrovascular accidents; avoid antipsychotic use for behavioral problems associated with dementia unless alternative nonpharmacologic therapies have failed and patient may harm self or others. In addition, use may cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults. May also be inappropriate in older adults depending on comorbidities (eg, dementia, delirium) due to its potent anticholinergic effects  (Beers Criteria).  Increased risk for developing tardive dyskinesia, particularly elderly women.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F210026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak), CYP2D6 (weak), CYP2E1 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F209966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotics. Severe extrapyramidal symptoms have occurred in some patients.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antipsychotics may diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-Parkinson's Agents (Dopamine Agonist): May diminish the therapeutic effect of Antipsychotics (Typical). Antipsychotics (Typical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist). Management: Avoid concomitant therapy if possible and monitor for decreased effects of both agents when these combinations cannot be avoided. Atypical antipsychotics such as clozapine and quetiapine may be less likely to reduce the effects of anti-Parkinson's agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: May enhance the QTc-prolonging effect of Pimozide. Crizotinib may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Weak): May increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May enhance the arrhythmogenic effect of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: May decrease the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May increase the serum concentration of Pimozide. The active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium formulations: May enhance the neurotoxic effect of Antipsychotics. Lithium formulations may decrease the serum concentration of Antipsychotics. Specifically noted with chlorpromazine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May enhance the QTc-prolonging effect of Pimozide. Macrolide Antibiotics may decrease the metabolism of Pimozide. This mechanism may not apply to azithromycin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antipsychotics may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Pimozide. Mifepristone may increase the serum concentration of Pimozide. Management: Avoid pimozide during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nefazodone: May increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the metabolism of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinagolide: Antipsychotics may diminish the therapeutic effect of Quinagolide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the adverse/toxic effect of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: Antipsychotics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zileuton: May increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F209989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol may increase CNS depression. Management: Monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Pimozide serum concentration may be increased when taken with grapefruit juice due to CYP3A4 inhibition. Management: Avoid concurrent use with grapefruit juice.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease pimozide levels through induction of CYP3A4. Kava kava, gotu kola, and valerian may increase CNS depression. Management: Avoid St John's wort, kava kava, gotu kola, and valerian.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F209967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7883517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies. Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F210002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F209981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Orap Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $172.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $230.38",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F209970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     ECG should be performed baseline and periodically thereafter, especially during dosage adjustment; vital signs; electrolytes, lipid profile, fasting blood glucose/Hgb A",
"     <sub>",
"      1c",
"     </sub>",
"     ; BMI; mental status, abnormal involuntary movement scale (AIMS), extrapyramidal symptoms (EPS); CYP2D6 genotyping or phenotyping",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F209982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Fopo (TW);",
"     </li>",
"     <li>",
"      Mozep (IN);",
"     </li>",
"     <li>",
"      Orap (1 mg) (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, HK, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Orap (4 mg) (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Orap (AR, AT, AU, BE, BR, CH, CZ, DE, DK, ES, FR, GB, HR, IE, IT, JP, LU, NL, NO, PL, VE);",
"     </li>",
"     <li>",
"      Orap Forte (4 mg) (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, HK, ID, IL, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, PT, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Pimodac (IN);",
"     </li>",
"     <li>",
"      Pirium (GR);",
"     </li>",
"     <li>",
"      Pizide (TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F209960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pimozide, a diphenylbutylperidine conventional antipsychotic, is a potent centrally-acting dopamine-receptor antagonist resulting in its characteristic neuroleptic effects",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F209977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: &ge;50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via N-dealkylation primarily by CYP3A4, but with contributions by CYP1A2 and CYP2D6; significant first-pass effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~55 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 6-8 hours (range: 4-12 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/20/6472/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bruggeman R, van der Linden C, Buitelaar JK, et al, &ldquo;Risperidone Versus Pimozide in Tourette's Disorder: A Comparative Double-Blind Parallel-Group Study,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 2001, 62(1):50-6.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bruun RD, &ldquo;Subtle and Under-Recognized Side Effects of Neuroleptic Treatment in Children With Tourette's Disorder,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 1988, 145(5):621-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/20/6472/abstract-text/2895987/pubmed\" id=\"2895987\" target=\"_blank\">",
"        2895987",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gill SS, Bronskill SE, Normand SL, et al, &ldquo;Antipsychotic Drug Use and Mortality in Older Adults With Dementia,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2007, 146(11):775-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/20/6472/abstract-text/17548409/pubmed\" id=\"17548409\" target=\"_blank\">",
"        17548409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health , &ldquo;Schizophrenia. Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Updated),&rdquo; National Clinical Practice Guideline Number 82, 2009:1-399. Available at  www.nice.org.uk/cg082",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rabins PV, Blacker D, Rovner BW, et al, &ldquo;American Psychiatric Association Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias. Second Edition,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2007, 164(12 Suppl):5-56.  Available at file://psychiatryonline.org/guidelines.aspx",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/20/6472/abstract-text/18340692/pubmed\" id=\"18340692\" target=\"_blank\">",
"        18340692",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schneeweiss S, Setoguchi S, Brookhart A, et al, &ldquo;Risk of Death Associated With the Use of Conventional Versus Atypical Antipsychotic Drugs Among Elderly Patients,&rdquo;",
"      <i>",
"       CMAJ",
"      </i>",
"      , 2007, 176(5): 627-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/20/6472/abstract-text/17325327/pubmed\" id=\"17325327\" target=\"_blank\">",
"        17325327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9773 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-8913731101-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_20_6472=[""].join("\n");
var outline_f6_20_6472=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7290571\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209993\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209994\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210031\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209997\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210014\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209998\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7883543\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209972\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209957\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209975\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210028\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14100513\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210029\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209978\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209961\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210026\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209966\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209989\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209967\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7883517\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210002\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209981\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209970\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209982\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209960\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209977\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9773\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9773|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/48/4869?source=related_link\">",
"      Pimozide: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/22/34151?source=related_link\">",
"      Pimozide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_20_6473="Overview of the acute management of tachyarrhythmias";
var content_f6_20_6473=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the acute management of tachyarrhythmias",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/20/6473/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/20/6473/contributors\">",
"     Philip J Podrid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/20/6473/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/20/6473/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/20/6473/contributors\">",
"     James Hoekstra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/20/6473/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/20/6473/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/20/6473/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 10, 2008.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important clinical decision a clinician must make in the evaluation of a patient with a rapid heart rate is whether the patient is also experiencing signs and symptoms related to the rapid heart rate. These include hypotension, heart failure or pulmonary congestion, shortness of breath, renal failure, shock, decreased level of consciousness, angina, or acute myocardial infarction. Immediate cardioversion is recommended in patients with these symptoms.",
"   </p>",
"   <p>",
"    For a relatively stable patient with a tachycardia not in need of immediate cardioversion, the emphasis is on:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Establishing a specific diagnosis for the rhythm",
"     </li>",
"     <li>",
"      Recognizing those patients who have significantly impaired left ventricular function (left ventricular ejection fraction [LVEF] &lt;40 percent or overt signs of heart failure)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The tachycardia overview algorithm recommended by the International Liaison Committee on Resuscitation (ILCOR) divides tachycardias into four diagnostic categories [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6473/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Irregular tachycardias - atrial fibrillation, atrial flutter, multifocal atrial tachycardia (MAT)",
"     </li>",
"     <li>",
"      Regular narrow complex tachycardias - sinus tachycardia and supraventricular tachycardia (reentry SVT)",
"     </li>",
"     <li>",
"      Wide complex tachycardias of unknown type - ventricular tachycardia (VT), SVT with aberrancy, pre-excited tachycardias",
"     </li>",
"     <li>",
"      Polymorphic (irregular) VT",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Guidelines for the management of these arrhythmias will be presented here. They are, in part, based upon the guidelines published in November 2005 by American Heart Association in collaboration with ILCOR (",
"    <a class=\"graphic graphic_algorithm graphicRef78734 graphicRef73601 graphicRef81052 \" href=\"UTD.htm?9/16/9481\">",
"     algorithm 1A-C",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6473/abstract/1\">",
"     1",
"    </a>",
"    ]. More complete reviews of the individual arrhythmias are discussed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ATRIAL FIBRILLATION AND ATRIAL FLUTTER",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the ECG demonstrates atrial fibrillation, atrial flutter or MAT, management focuses on control of the rapid ventricular rate (rate control) and conversion of hemodynamically unstable arrhythmia to sinus rhythm (rhythm control). Atrial tachycardia with multiple foci (MAT) must be distinguished from atrial fibrillation since both present with an irregularly irregular rhythm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/20/38216?source=see_link\">",
"     \"Multifocal atrial tachycardia\"",
"    </a>",
"    .) Cardioversion and standard antiarrhythmic drugs are typically ineffective in MAT [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6473/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/20/38216?source=see_link\">",
"     \"Multifocal atrial tachycardia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The focus of the initial evaluation is the stability of the patient, the state of left ventricular function, the presence of the Wolff-Parkinson-White (WPW) syndrome, and the duration of the arrhythmia (greater than or less than 48 hours). The urgency of treatment depends upon the clinical stability of the patient (",
"    <a class=\"graphic graphic_table graphicRef68352 graphicRef80760 \" href=\"UTD.htm?8/9/8350\">",
"     table 1A-B",
"    </a>",
"    ) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=see_link\">",
"     \"Overview of atrial fibrillation\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urgent cardioversion is indicated for those patients who are hemodynamically unstable. However, cardioversion is ineffective in multifocal atrial tachycardia [",
"      <a class=\"abstract\" href=\"UTD.htm?6/20/6473/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/20/38216?source=see_link\">",
"       \"Multifocal atrial tachycardia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who are hemodynamically stable should be treated with drugs that slow the ventricular rate by inhibiting or slowing conduction through the atrioventricular node.",
"     </li>",
"     <li>",
"      When indicated, stable patients can undergo pharmacologic or electrical cardioversion of a less urgent, and more controlled manner.",
"     </li>",
"     <li>",
"      Provide anticoagulation if indicated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When deciding upon a treatment plan for acute therapy of atrial fibrillation or atrial flutter there are a number of considerations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Is left ventricular function normal or impaired?",
"     </li>",
"     <li>",
"      Does the patient have WPW?",
"     </li>",
"     <li>",
"      What is the duration of atrial fibrillation and can the time of onset be reliably established? Is the duration less than or more than 48 hours?",
"     </li>",
"     <li>",
"      Is anticoagulation indicated?",
"     </li>",
"     <li>",
"      Can the patient undergo electrical cardioversion safely?",
"     </li>",
"     <li>",
"      Would pharmacologic conversion be preferable? Does it pose a higher risk of emboli?",
"     </li>",
"     <li>",
"      Is the ventricular rate too high?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Treatment of AF or atrial flutter when left ventricular function is normal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended approach to slow the ventricular rate, regardless of the duration of the arrhythmia, is the use either a beta blocker or a calcium channel blocker (class I) (",
"    <a class=\"graphic graphic_table graphicRef68352 \" href=\"UTD.htm?5/43/5821\">",
"     table 1A",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6473/abstract/3-7\">",
"     3-7",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    is an alternative agent, however, it is relatively impotent and has a slow onset of action. Digoxin works primarily by enhancing vagal tone, which is usually low when AF is of recent onset.",
"   </p>",
"   <p>",
"    When these therapies are ineffective or contraindicated, intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    may be used.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/26/44454?source=see_link\">",
"     Adenosine",
"    </a>",
"    is an inappropriate agent (class III) because of its very short duration of action. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The approach to the conversion of atrial fibrillation or atrial flutter is dependent upon its duration (",
"    <a class=\"graphic graphic_table graphicRef68352 graphicRef80760 \" href=\"UTD.htm?8/9/8350\">",
"     table 1A-B",
"    </a>",
"    ) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=see_link\">",
"     \"Restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    ):",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Duration &lt;48 hours",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electric cardioversion is the preferred treatment for the restoration of sinus rhythm. Patients who do not have valvular heart disease, an enlarged left ventricle or heart failure, or a prior history of an embolic event are at low risk for embolism [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6473/abstract/8\">",
"     8",
"    </a>",
"    ]; as a result, cardioversion does not need to be delayed for chronic anticoagulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=see_link\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pharmacologic therapy is recommended if electric cardioversion is not feasible or desirable or is unsuccessful for restoring or maintaining sinus rhythm. Recommended agents (class IIa) include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    ; alternative agents (class IIb) are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6473/abstract/9-16\">",
"     9-16",
"    </a>",
"    ]. Other recommended agents include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    or magnesium [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6473/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=see_link\">",
"     \"Restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Duration &ge;48 hours or unknown",
"    </span>",
"    &nbsp;&mdash;&nbsp;When AF is of longer duration, there is an increased risk of embolism from an atrial thrombus; as a result, pharmacologic or electric cardioversion should be delayed until there has been at least three weeks of adequate anticoagulation (INR 2 to 3). Adequate anticoagulation should be continued for at least four weeks thereafter because of \"atrial stunning\" and the potential risk for embolism despite sinus rhythm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=see_link\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who might benefit from earlier cardioversion because of hemodynamic problems, early cardioversion is an option. However, in such patients the presence if an atrial thrombus must be excluded. Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is begun immediately and a transesophageal echocardiogram is performed to exclude left atrial thrombus; in the absence of thrombus, cardioversion is performed within 24 hours and anticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is continued for four weeks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=see_link\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/50/2856?source=see_link\">",
"     \"Role of echocardiography in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Treatment of AF or atrial flutter when left ventricular function is impaired",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of left ventricular systolic dysfunction (left ventricular ejection fraction &le;40 percent or overt heart failure) the recommended drug for rate control is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    . Beta blockers,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    may be used as alternative or additional treatments, but with caution, particularly in patients with clinical evidence of heart failure. (",
"    <a class=\"graphic graphic_table graphicRef68352 \" href=\"UTD.htm?5/43/5821\">",
"     table 1A",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The approach to conversion of the arrhythmia depends upon duration:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Duration &lt;48 hours",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrical cardioversion is the preferred treatment. If this is not feasible, desirable, or effective, the recommended therapy is intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    . Alternative agents are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Duration &ge;48 hours",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended approach is three weeks of adequate anticoagulation followed by electric cardioversion; anticoagulation should be continued for at least four weeks thereafter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Treatment in the presence of WPW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with atrial fibrillation or atrial flutter associated with WPW have normal left ventricular function and the preferred approach is cardioversion (",
"    <a class=\"graphic graphic_table graphicRef80760 \" href=\"UTD.htm?34/25/35228\">",
"     table 1B",
"    </a>",
"    ). However, if cardioversion is not feasible, desirable, or effective, antiarrhythmic drugs that have direct on the accessory pathway conduction and refractoriness are acceptable alternatives for rate control (class IIb); these agents may also be useful for pharmacologic conversion of the arrhythmia when it has been present for less than 48 hours. Recommended drugs include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6473/abstract/17-21\">",
"     17-21",
"    </a>",
"    ]. The drug of choice for more immediate effect is intravenous procainamide. Intravenous preparations of flecainide and propafenone are not available in the US.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"     Ibutilide",
"    </a>",
"    is also an effective agent. A third line agent is amiodarone. Drugs for rate control or pharmacologic reversion that may be",
"    <strong>",
"     harmful",
"    </strong>",
"    and are contraindicated include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/26/44454?source=see_link\">",
"     adenosine",
"    </a>",
"    , beta blockers, calcium channel blockers, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    When the arrhythmia has been present for more than 48 hours or an unknown duration, the recommended therapy is three weeks of adequate anticoagulation and then electric cardioversion followed by an additional four weeks of anticoagulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     REGULAR NARROW COMPLEX TACHYCARDIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The narrow complex tachycardias include junctional tachycardia; atrial tachycardias (ectopic or reentrant); and paroxysmal supraventricular tachycardias, including atrioventricular nodal reentrant tachycardia (AVNRT) and atrioventricular reentrant tachycardia (AVRT) associated with the WPW syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24793?source=see_link\">",
"     \"Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24311?source=see_link\">",
"     \"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prior to initiating therapy, a specific diagnosis must be established by close inspection of the ECG and then, if necessary, using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/26/44454?source=see_link\">",
"     adenosine",
"    </a>",
"    or vagal maneuvers (",
"    <a class=\"graphic graphic_algorithm graphicRef73601 \" href=\"UTD.htm?14/35/14896\">",
"     algorithm 1B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6473/abstract/22\">",
"     22",
"    </a>",
"    ]. There are several cautions with the use of adenosine:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients treated with methylxanthines (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      ) are less sensitive to the effects of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/26/44454?source=see_link\">",
"       adenosine",
"      </a>",
"      because the methylxanthines have adenosine receptor antagonist activity",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       Dipyridamole",
"      </a>",
"      , which blocks the transport of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/26/44454?source=see_link\">",
"       adenosine",
"      </a>",
"      back into cells, may enhance the sensitivity to adenosine",
"     </li>",
"     <li>",
"      Cardiac denervation after cardiac transplantation may result in an exaggerated bradycardic response to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/26/44454?source=see_link\">",
"       adenosine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/26/44454?source=see_link\">",
"       Adenosine",
"      </a>",
"      can provoke bronchospasm and must be used cautiously in patients with reactive airway disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some situations, consultation with a cardiologist may be required. The approach to establishing the etiology of a narrow complex tachycardia is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Junctional tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Junctional tachycardia is uncommon in adults and is most commonly a misdiagnosed AVNRT or AVRT. True junctional tachycardia, which is generally the result of an ectopic focus in the AV junction that manifests enhanced automaticity, is usually a manifestation of digitalis toxicity or excessive use of exogenous catecholamines or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    ; these agents should be withdrawn. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28072?source=see_link\">",
"     \"Basic approach to arrhythmias due to digoxin toxicity\"",
"    </a>",
"    .) Electric cardioversion should",
"    <strong>",
"     not",
"    </strong>",
"    be used in these situations, as it is ineffective for terminating arrhythmias due to enhanced automaticity. Cardioversion is also potentially harmful in the setting of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    toxicity. When the etiology of the junctional tachycardia is uncertain or if the arrhythmia persists after withdrawal of the causative agent, recommended therapy (class IIb) in the absence of left ventricular dysfunction is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , beta blockers, or calcium channel blockers; in the presence of left ventricular dysfunction, the recommended therapy is amiodarone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Paroxysmal supraventricular tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;When AVNRT or AVRT is refractory to vagal maneuvers or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/26/44454?source=see_link\">",
"     adenosine",
"    </a>",
"    , effective therapy for termination of the arrhythmia includes a calcium channel blocker, beta blocker, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , which may have a slow onset of action [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6473/abstract/6\">",
"     6",
"    </a>",
"    ]. If the arrhythmia persists, electric cardioversion should be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11050?source=see_link\">",
"     \"Cardioversion for specific arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary antiarrhythmic drugs can destabilize these patients because of their hypotensive effects and the potential for proarrhythmia. As a result, they should be considered only if the administration of an AV nodal blocking agent or electrical cardioversion is not feasible, desirable, or successful. Calcium channel blockers, beta blockers, and primary antiarrhythmic agents should",
"    <strong>",
"     not",
"    </strong>",
"    be serially administered because of potential additive negative hypotensive, bradycardic, and proarrhythmic effects. Recommended (class IIa) antiarrhythmic drugs are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6473/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For the patient with significant left ventricular dysfunction,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , or perhaps",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    are the preferred AV nodal blocking agents (class IIb); other antiarrhythmic agents, beta blockers, and calcium channel blockers should be",
"    <strong>",
"     avoided",
"    </strong>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Atrial tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regular atrial tachycardias are usually the result of a single ectopic atrial focus that manifests enhanced automaticity, is often secondary to other conditions (most often lung disease) or the use of catecholamines or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    . Thus, supportive measures and treatment of the precipitating causes are often effective. Cardioversion should",
"    <strong>",
"     not",
"    </strong>",
"    be employed since it is ineffective.",
"   </p>",
"   <p>",
"    Recommended therapy in the absence of left ventricular dysfunction consists of calcium channel blockers, beta blockers, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6473/abstract/25\">",
"     25",
"    </a>",
"    ]. These agents most often achieve rate control by blocking conduction through the AV node and less often result in arrhythmia reversion. Other acceptable therapies for atrial tachycardia that are more likely to result in arrhythmia reversion are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6473/abstract/26\">",
"     26",
"    </a>",
"    ];",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    are also effective, although have a higher incidence of side effects. In patients with left ventricular dysfunction, preferred therapy (class IIb) includes",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    , amiodarone, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     WIDE COMPLEX TACHYCARDIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most concerning potential cause of a wide complex tachycardia is ventricular tachycardia. Wide complex tachycardias may also be caused by supraventricular arrhythmias (eg, sinus tachycardia, atrial tachycardia, atrial flutter or AVNRT) with aberrant conduction that is rate related (functional block) or that is preexistent, or by an antidromic AVRT in patients with WPW. One additional cause is a pacemaker associated tachycardia; in this situation, pacemaker spikes are usually seen.",
"   </p>",
"   <p>",
"    Prior to therapy, it is very important that the etiology be established [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6473/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The mechanism of a WCT can be determined with clinical information, close analysis of the 12 lead ECG (eg, for the presence of AV dissociation), or with an esophageal lead [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6473/abstract/28-33\">",
"     28-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/26/44454?source=see_link\">",
"     adenosine",
"    </a>",
"    is an effective therapy for establishing the etiology of a narrow complex tachycardia and for terminating AVNRT or AVRT, it is ineffective and potentially deleterious in patients with ventricular tachycardia. Adenosine has vasodilatory effects that, despite being short-lived, can worsen hypotension in patients with ventricular tachycardia who are barely compensated; it may also cause proarrhythmia and acceleration of accessory pathway conduction [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6473/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. For these reasons, adenosine is",
"    <strong>",
"     not recommended",
"    </strong>",
"    to establish the etiology of a wide complex tachycardia of uncertain etiology and to discriminate between ventricular and supraventricular tachycardia.",
"   </p>",
"   <p>",
"    A more in depth discussion about the differentiation between a supraventricular tachycardia with aberration versus ventricular tachycardia is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31034?source=see_link\">",
"     \"Approach to the diagnosis and treatment of wide QRS complex tachycardias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Hemodynamically unstable arrhythmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of the cause, a wide complex tachycardia that is rapid (&gt;150",
"    <span class=\"nowrap\">",
"     beats/min),",
"    </span>",
"    unstable, and associated with serious hemodynamic compromise must be treated promptly with electric cardioversion (",
"    <a class=\"graphic graphic_algorithm graphicRef74033 \" href=\"UTD.htm?42/17/43294\">",
"     algorithm 2",
"    </a>",
"    ). If the patient is unconscious, electrical reversion is urgent; in the conscious patient, a brief trial of medications, based upon the etiology of the arrhythmia, may be attempted prior to cardioversion.",
"   </p>",
"   <p>",
"    It is recommended that the patient be monitored with an oxygen saturation monitor, and that intravenous access be obtained prior to cardioversion. Also, a suction device and intubation equipment should be available at the bedside.",
"   </p>",
"   <p>",
"    Prior to cardioversion, the conscious patient should be premedicated with a sedative or analgesic agent. Effective sedative regimens include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    , barbiturates,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/15/24823?source=see_link\">",
"     methohexital",
"    </a>",
"    ; effective analgesic agents include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"     meperidine",
"    </a>",
"   </p>",
"   <p>",
"    Synchronized cardioversion is used for monomorphic ventricular tachycardia, paroxysmal AVNRT or AVRT, atrial fibrillation, or atrial flutter. When the device delivers a monophasic waveform, initial energies are 50 to 100 joules and are increased in a stepwise fashion to 360 joules; energies of &le;200 joules are generally effective when a biphasic waveform is delivered.",
"   </p>",
"   <p>",
"    If synchronization is not possible or is delayed or if the patient's clinical status deteriorates, defibrillation (unsynchronized shock) should be used. Defibrillation is also necessary if the arrhythmia is polymorphic ventricular tachycardia, very rapid ventricular tachycardia with rates &gt;260 (often called ventricular flutter), or certainly ventricular fibrillation. A detailed discussion of cardioversion and defibrillation is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17977?source=see_link\">",
"     \"Basic principles and technique of cardioversion and defibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11050?source=see_link\">",
"     \"Cardioversion for specific arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Polymorphic ventricular tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymorphic (or polymorphous) ventricular tachycardia (VT) is defined as an unstable rhythm with a continuously varying QRS complex morphology in any recorded electrocardiographic (ECG) lead (",
"    <a class=\"graphic graphic_waveform graphicRef54538 \" href=\"UTD.htm?7/6/7271\">",
"     waveform 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6473/abstract/1\">",
"     1",
"    </a>",
"    ]. The simultaneous recording of more than one ECG lead is often necessary to detect these changes.",
"   </p>",
"   <p>",
"    Polymorphic VT is generally a rapid and hemodynamically unstable rhythm, and urgent defibrillation is usually necessary. In addition to immediate cardioversion, further therapy is intended to treat underlying disorders and to prevent recurrences. The specific approach depends upon whether or not the QT interval on the baseline ECG is prolonged. Polymorphic VT that occurs in the setting of QT prolongation is considered as a distinct arrhythmia, called torsades de pointes, which is discussed separately below.",
"   </p>",
"   <p>",
"    In the absence of QT interval prolongation, polymorphic VT is most often due to ischemia, which may be overt or silent. Ischemia may be due to epicardial coronary artery disease or left ventricular hypertrophy. In addition, polymorphic VT can be due to an inherited primary arrhythmia syndrome, called familial catecholaminergic polymorphic VT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=see_link\">",
"     \"Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/European",
"    </span>",
"    Society of Cardiology",
"    <span class=\"nowrap\">",
"     (ACC/AHA/ESC)",
"    </span>",
"    guidelines for the management of ventricular arrhythmias and the prevention of sudden cardiac death included recommendations for the management of polymorphic VT [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6473/abstract/37\">",
"     37",
"    </a>",
"    ]. Because acute management decisions are often made in the absence of a detailed knowledge of underlying cardiac disease, the recommendations do not make clear distinctions based upon the presence of CHD or familial disease.",
"   </p>",
"   <p>",
"    The guidelines stated that evidence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    general agreement strongly support the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If hemodynamic compromise is present, immediate direct current cardioversion should be performed.",
"     </li>",
"     <li>",
"      Intravenous beta blockers for recurrent polymorphic VT, especially if ischemia is suspected or cannot be excluded.",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      for recurrent polymorphic VT in the absence of congenital or acquired QT interval prolongation.",
"     </li>",
"     <li>",
"      Urgent angiography if myocardial ischemia cannot be excluded.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Torsades de pointes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymorphic VT associated with a prolonged QT interval is termed torsades de pointes (TdP). TdP can occur in patients who have a congenital long QT syndrome or acquired QT prolongation from drug therapy, hypomagnesemia, or hypokalemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=see_link\">",
"     \"Clinical features of congenital long QT syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26682?source=see_link\">",
"     \"Prognosis and management of congenital long QT syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TdP is often triggered by a VPC that occurs during the prolonged repolarization period (the electrophysiologic phenomenon underlying QT prolongation). The risk of such an event is greater during episodes of bradycardia or following a ventricular pause. Thus, some of the therapies are intended to treat bradycardia (eg, cardiac pacing or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    ). The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA/ESC",
"    </span>",
"    guidelines included recommendations for the management of TdP [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6473/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The guidelines stated that evidence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    general agreement strongly support the following interventions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Withdrawal of any offending drugs and correction of electrolyte abnormalities.",
"     </li>",
"     <li>",
"      Acute pacing for urgent therapy of drug induced TdP. Long-term cardiac pacing in patients with TdP presenting with heart block and symptomatic bradycardia.",
"     </li>",
"     <li>",
"      Beta blocker therapy for patients with congenital QT prolongation and TdP. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26682?source=see_link\">",
"       \"Prognosis and management of congenital long QT syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The guidelines suggest that the weight of evidence supports the following (weaker recommendations):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      for patients with drug-induced QT prolongation and few episodes of TdP [",
"      <a class=\"abstract\" href=\"UTD.htm?6/20/6473/abstract/38,39\">",
"       38,39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Acute and long-term cardiac pacing for patients who have recurrent, pause-dependent TdP [",
"      <a class=\"abstract\" href=\"UTD.htm?6/20/6473/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Beta blockers combined with cardiac pacing as acute therapy for patients with TdP and sinus bradycardia.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"       Isoproterenol",
"      </a>",
"      as temporary treatment in patients with recurrent pause-dependent TdP who do not have congenital long QT syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The guidelines also suggest that the following interventions may be considered, although supporting evidence is less well-established:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Potassium repletion to 4.5 to 5",
"      <span class=\"nowrap\">",
"       mmol/liter.",
"      </span>",
"     </li>",
"     <li>",
"      For patients with long QT syndrome 3 (LQT3) and TdP, intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      or oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/9/10389?source=see_link\">",
"       mexiletine",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Monomorphic ventricular tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stable monomorphic ventricular tachycardia can be treated promptly with electric cardioversion, as discussed above (",
"    <a class=\"graphic graphic_algorithm graphicRef81052 \" href=\"UTD.htm?25/26/26016\">",
"     algorithm 1C",
"    </a>",
"    ). However, if left ventricular function is normal and there is no heart failure, pharmacologic therapy for reversion is acceptable. Recommended agents (class IIa) are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    ; other acceptable agents (class IIb) include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6473/abstract/41-45\">",
"     41-45",
"    </a>",
"    ]. Only one agent should be used to avoid proarrhythmic and other potential adverse effects resulting from combination therapy.",
"   </p>",
"   <p>",
"    In the patient with impaired left ventricular function (left ventricular ejection fraction &lt;40 percent or heart failure), recommended therapy (class IIb) is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      &mdash; Amiodarone is given as a 150 mg (or 5",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      intravenous bolus over 10 minutes; additional boluses of 150 mg over 10 minutes are given every 10 to 15 minutes as needed. Alternatively, an infusion of 360 mg (1",
"      <span class=\"nowrap\">",
"       mg/min)",
"      </span>",
"      over six hours followed by 540 mg (0.5",
"      <span class=\"nowrap\">",
"       mg/min)",
"      </span>",
"      over the remaining 18 hours can be used. The maximum total dose (including doses given during resuscitation) is 2.2 grams in 24 hours. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38857?source=see_link\">",
"       \"Clinical uses of amiodarone\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       Lidocaine",
"      </a>",
"      &mdash; Lidocaine is administration by intravenous push in a dose of 0.5 to 0.75",
"      <span class=\"nowrap\">",
"       mg/kg;",
"      </span>",
"      this dose is repeated every 5 to 10 minutes as needed. At the same time, a continuous intravenous infusion of 1 to 4",
"      <span class=\"nowrap\">",
"       mg/min",
"      </span>",
"      is begun. The maximum total dose is 3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      over one hour.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/34/5666?source=see_link\">",
"       \"Patient information: Tachycardia (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/51/27442?source=see_link\">",
"       \"Patient information: Ventricular tachycardia (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/45/11986?source=see_link\">",
"       \"Patient information: Supraventricular tachycardia (SVT) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/1\">",
"      International Liaison Committee on Resuscitation. 2005 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations. Part 1: introduction. Resuscitation 2005; 67:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/2\">",
"      Kastor JA. Multifocal atrial tachycardia. N Engl J Med 1990; 322:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/3\">",
"      Farshi R, Kistner D, Sarma JS, et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol 1999; 33:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/4\">",
"      Platia EV, Michelson EL, Porterfield JK, Das G. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. Am J Cardiol 1989; 63:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/5\">",
"      Lundstr&ouml;m T, Ryd&eacute;n L. Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of diltiazem and verapamil. J Am Coll Cardiol 1990; 16:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/6\">",
"      Ellenbogen KA, Dias VC, Cardello FP, et al. Safety and efficacy of intravenous diltiazem in atrial fibrillation or atrial flutter. Am J Cardiol 1995; 75:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/7\">",
"      Salerno DM, Dias VC, Kleiger RE, et al. Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter. The Diltiazem-Atrial Fibrillation/Flutter Study Group. Am J Cardiol 1989; 63:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/8\">",
"      Weigner MJ, Caulfield TA, Danias PG, et al. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med 1997; 126:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/9\">",
"      Galve E, Rius T, Ballester R, et al. Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol 1996; 27:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/10\">",
"      Stambler BS, Wood MA, Ellenbogen KA. Comparative efficacy of intravenous ibutilide versus procainamide for enhancing termination of atrial flutter by atrial overdrive pacing. Am J Cardiol 1996; 77:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/11\">",
"      Donovan KD, Power BM, Hockings BE, et al. Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation. Am J Cardiol 1995; 75:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/12\">",
"      Kochiadakis GE, Igoumenidis NE, Simantirakis EN, et al. Intravenous propafenone versus intravenous amiodarone in the management of atrial fibrillation of recent onset: a placebo-controlled study. Pacing Clin Electrophysiol 1998; 21:2475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/13\">",
"      Mattioli AV, Lucchi GR, Vivoli D, Mattioli G. Propafenone versus procainamide for conversion of atrial fibrillation to sinus rhythm. Clin Cardiol 1998; 21:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/14\">",
"      Kochiadakis GE, Igoumenidis NE, Solomou MC, et al. Conversion of atrial fibrillation to sinus rhythm using acute intravenous procainamide infusion. Cardiovasc Drugs Ther 1998; 12:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/15\">",
"      Sung RJ, Tan HL, Karagounis L, et al. Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. Sotalol Multicenter Study Group. Am Heart J 1995; 129:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/16\">",
"      Fuster V, Ryd&eacute;n LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114:e257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/17\">",
"      Kuga K, Yamaguchi I, Sugishita Y. Effect of intravenous amiodarone on electrophysiologic variables and on the modes of termination of atrioventricular reciprocating tachycardia in Wolff-Parkinson-White syndrome. Jpn Circ J 1999; 63:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/18\">",
"      O'Nunain S, Garratt CJ, Linker NJ, et al. A comparison of intravenous propafenone and flecainide in the treatment of tachycardias associated with the Wolff-Parkinson-White syndrome. Pacing Clin Electrophysiol 1991; 14:2028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/19\">",
"      Boahene KA, Klein GJ, Yee R, et al. Termination of acute atrial fibrillation in the Wolff-Parkinson-White syndrome by procainamide and propafenone: importance of atrial fibrillatory cycle length. J Am Coll Cardiol 1990; 16:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/20\">",
"      Mandel WJ, Laks MM, Obayashi K, et al. The Wolff-Parkinson-White syndrome: pharmacologic effects of procaine amide. Am Heart J 1975; 90:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/21\">",
"      Touboul P, Atallah G, Kirkorian G, et al. Effects of intravenous sotalol in patients with atrioventricular accessory pathways. Am Heart J 1987; 114:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/22\">",
"      Camm AJ, Garratt CJ. Adenosine and supraventricular tachycardia. N Engl J Med 1991; 325:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/23\">",
"      Jordaens L, Gorgels A, Stroobandt R, Temmerman J. Efficacy and safety of intravenous sotalol for termination of paroxysmal supraventricular tachycardia. The Sotalol Versus Placebo Multicenter Study Group. Am J Cardiol 1991; 68:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/24\">",
"      Hellestrand KJ. Intravenous flecainide acetate for supraventricular tachycardias. Am J Cardiol 1988; 62:16D.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/25\">",
"      Kouvaras G, Cokkinos DV, Halal G, et al. The effective treatment of multifocal atrial tachycardia with amiodarone. Jpn Heart J 1989; 30:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/26\">",
"      Kuck KH, Kunze KP, Schl&uuml;ter M, Duckeck W. Encainide versus flecainide for chronic atrial and junctional ectopic tachycardia. Am J Cardiol 1988; 62:37L.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/27\">",
"      Stewart RB, Bardy GH, Greene HL. Wide complex tachycardia: misdiagnosis and outcome after emergent therapy. Ann Intern Med 1986; 104:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/28\">",
"      Akhtar M, Shenasa M, Jazayeri M, et al. Wide QRS complex tachycardia. Reappraisal of a common clinical problem. Ann Intern Med 1988; 109:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/29\">",
"      Brugada P, Brugada J, Mont L, et al. A new approach to the differential diagnosis of a regular tachycardia with a wide QRS complex. Circulation 1991; 83:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/30\">",
"      Antunes E, Brugada J, Steurer G, et al. The differential diagnosis of a regular tachycardia with a wide QRS complex on the 12-lead ECG: ventricular tachycardia, supraventricular tachycardia with aberrant intraventricular conduction, and supraventricular tachycardia with anterograde conduction over an accessory pathway. Pacing Clin Electrophysiol 1994; 17:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/31\">",
"      Kindwall KE, Brown J, Josephson ME. Electrocardiographic criteria for ventricular tachycardia in wide complex left bundle branch block morphology tachycardias. Am J Cardiol 1988; 61:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/32\">",
"      Alberca T, Almendral J, Sanz P, et al. Evaluation of the specificity of morphological electrocardiographic criteria for the differential diagnosis of wide QRS complex tachycardia in patients with intraventricular conduction defects. Circulation 1997; 96:3527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/33\">",
"      Andrade FR, Eslami M, Elias J, et al. Diagnostic clues from the surface ECG to identify idiopathic (fascicular) ventricular tachycardia: correlation with electrophysiologic findings. J Cardiovasc Electrophysiol 1996; 7:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/34\">",
"      Sharma AD, Klein GJ, Yee R. Intravenous adenosine triphosphate during wide QRS complex tachycardia: safety, therapeutic efficacy, and diagnostic utility. Am J Med 1990; 88:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/35\">",
"      Garratt CJ, Griffith MJ, O'Nunain S, et al. Effects of intravenous adenosine on antegrade refractoriness of accessory atrioventricular connections. Circulation 1991; 84:1962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/36\">",
"      Brodsky MA, Hwang C, Hunter D, et al. Life-threatening alterations in heart rate after the use of adenosine in atrial flutter. Am Heart J 1995; 130:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/37\">",
"      European Heart Rhythm Association, Heart Rhythm Society, Zipes DP, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006; 48:e247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/38\">",
"      Tzivoni D, Keren A, Cohen AM, et al. Magnesium therapy for torsades de pointes. Am J Cardiol 1984; 53:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/39\">",
"      Tzivoni D, Banai S, Schuger C, et al. Treatment of torsade de pointes with magnesium sulfate. Circulation 1988; 77:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/40\">",
"      T&ouml;tterman KJ, Turto H, Pellinen T. Overdrive pacing as treatment of sotalol-induced ventricular tachyarrhythmias (torsade de pointes). Acta Med Scand Suppl 1982; 668:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/41\">",
"      Griffith MJ, Linker NJ, Garratt CJ, et al. Relative efficacy and safety of intravenous drugs for termination of sustained ventricular tachycardia. Lancet 1990; 336:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/42\">",
"      Ho DS, Zecchin RP, Richards DA, et al. Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia. Lancet 1994; 344:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/43\">",
"      Giardina EG, Heissenbuttel RH, Bigger JT Jr. Intermittent intravenous procaine amide to treat ventricular arrhythmias. Correlation of plasma concentration with effect on arrhythmia, electrocardiogram, and blood pressure. Ann Intern Med 1973; 78:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/44\">",
"      Sch&uuml;tzenberger W, Leisch F, Kerschner K, et al. Clinical efficacy of intravenous amiodarone in the short term treatment of recurrent sustained ventricular tachycardia and ventricular fibrillation. Br Heart J 1989; 62:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6473/abstract/45\">",
"      Naccarelli GV, Jalal S. Intravenous amiodarone. Another option in the acute management of sustained ventricular tachyarrhythmias. Circulation 1995; 92:3154.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 936 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-124.240.187.80-339106477A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_20_6473=[""].join("\n");
var outline_f6_20_6473=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ATRIAL FIBRILLATION AND ATRIAL FLUTTER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Treatment of AF or atrial flutter when left ventricular function is normal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Duration &lt;48 hours",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Duration &ge;48 hours or unknown",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Treatment of AF or atrial flutter when left ventricular function is impaired",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Duration &lt;48 hours",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Duration &ge;48 hours",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Treatment in the presence of WPW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      REGULAR NARROW COMPLEX TACHYCARDIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Junctional tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Paroxysmal supraventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Atrial tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      WIDE COMPLEX TACHYCARDIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Hemodynamically unstable arrhythmia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Polymorphic ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Torsades de pointes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Monomorphic ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/936\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/936|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?22/37/23123\" title=\"algorithm 1A\">",
"      Tachycardia overview algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?14/35/14896\" title=\"algorithm 1B\">",
"      Algorithm narrow complex SVT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?25/26/26016\" title=\"algorithm 1C\">",
"      ACLS algorithm stable VT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?42/17/43294\" title=\"algorithm 2\">",
"      ACLS algorithm cardioversion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/936|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/43/5821\" title=\"table 1A\">",
"      ACLS AF rate rhythm control I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/25/35228\" title=\"table 1B\">",
"      ACLS AF rate rhythm control II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/936|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?7/6/7271\" title=\"waveform 1\">",
"      ECG_1 Polymorphic VT in ischemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=related_link\">",
"      Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31034?source=related_link\">",
"      Approach to the diagnosis and treatment of wide QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24793?source=related_link\">",
"      Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24311?source=related_link\">",
"      Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28072?source=related_link\">",
"      Basic approach to arrhythmias due to digoxin toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17977?source=related_link\">",
"      Basic principles and technique of cardioversion and defibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11050?source=related_link\">",
"      Cardioversion for specific arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=related_link\">",
"      Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=related_link\">",
"      Clinical features of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38857?source=related_link\">",
"      Clinical uses of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/20/38216?source=related_link\">",
"      Multifocal atrial tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=related_link\">",
"      Overview of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/45/11986?source=related_link\">",
"      Patient information: Supraventricular tachycardia (SVT) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/34/5666?source=related_link\">",
"      Patient information: Tachycardia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/51/27442?source=related_link\">",
"      Patient information: Ventricular tachycardia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26682?source=related_link\">",
"      Prognosis and management of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=related_link\">",
"      Restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/50/2856?source=related_link\">",
"      Role of echocardiography in atrial fibrillation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_20_6474="Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris";
var content_f6_20_6474=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/20/6474/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/20/6474/contributors\">",
"     Diane Thiboutot, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/20/6474/contributors\">",
"     Andrea Zaenglein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/20/6474/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/20/6474/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/20/6474/contributors\">",
"     Moise L Levy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/20/6474/contributors\">",
"     Mark V Dahl, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/20/6474/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/20/6474/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/20/6474/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acne vulgaris is the most common cutaneous disorder affecting adolescents and young adults. Patients with acne can experience significant psychological morbidity and, rarely, mortality due to suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The psychological effects of embarrassment and anxiety can impact the social lives and employment of affected individuals. Scars can be disfiguring and lifelong. In one prospective study of 90 patients with acne, a significant improvement in self-esteem was found with treatment of the acne [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/3\">",
"     3",
"    </a>",
"    ]. Thus, it is imperative that clinicians are familiar with acne vulgaris and its treatment.",
"   </p>",
"   <p>",
"    The pathogenesis, clinical manifestations, diagnosis, and differential diagnosis of acne vulgaris will be reviewed here. The treatment of acne vulgaris is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39370?source=see_link\">",
"     \"Treatment of acne vulgaris\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44599?source=see_link\">",
"     \"Hormonal therapy for women with acne vulgaris\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/42/22184?source=see_link\">",
"     \"Oral isotretinoin therapy for acne vulgaris\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/54/33639?source=see_link\">",
"     \"Light-based, adjunctive, and other therapies for acne vulgaris\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimates of the prevalence of acne vulgaris in adolescents range from 35 to over 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Acne tends to resolve in the third decade, but it may persist into or develop de novo in adulthood. The exact prevalence in adults is uncertain, and studies using a clinical examination typically find a lower prevalence than surveys asking for patients to self-report acne.",
"   </p>",
"   <p>",
"    Post-adolescent acne predominantly affects women, in contrast to adolescent acne which has a male predominance [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/6\">",
"     6",
"    </a>",
"    ]. In one survey of over 1000 adults, self-reported acne in men and women was documented as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      20 to 29 years: 43 and 51 percent, respectively",
"     </li>",
"     <li>",
"      30 to 39 years: 20 and 35 percent, respectively",
"     </li>",
"     <li>",
"      40 to 49 years: 12 and 26 percent, respectively",
"     </li>",
"     <li>",
"      ages 50 and older: 7 and 15 percent, respectively",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The difference in the prevalence of acne in males and females was statistically significant in each age group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pilosebaceous follicles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acne vulgaris is a disease of pilosebaceous follicles. Four factors are involved (",
"    <a class=\"graphic graphic_figure graphicRef57892 \" href=\"UTD.htm?34/20/35146\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Follicular hyperkeratinization",
"     </li>",
"     <li>",
"      Increased sebum production",
"     </li>",
"     <li>",
"      Propionibacterium acnes (P. acnes) within the follicle",
"     </li>",
"     <li>",
"      Inflammation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The sequence of events leading to the development of an acne lesion is not fully understood. The earliest change in the pilosebaceous unit was initially thought to be follicular hyperkeratinization, which is associated with both increased proliferation and decreased desquamation of keratinocytes lining the follicular orifice. This results in partial obstruction of the follicle with sebum and keratin (the microcomedo). However, an influx of inflammatory cells in the perifollicular region may precede the changes in keratinization [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/7\">",
"     7",
"    </a>",
"    ]. Initiating factors for this inflammatory process are unknown.",
"   </p>",
"   <p>",
"    Sebaceous glands enlarge with adrenarche (the prepubertal period in which levels of DHEA-S rise) and sebum production increases. Sebum provides a growth medium for P. acnes, an anaerobic diphtheroid that is a normal component of skin flora. Microcomedones provide an anaerobic lipid-rich environment that allows these bacteria to thrive; they utilize triglycerides in sebum as a nutrient source by hydrolyzing them into free fatty acids and glycerol.",
"   </p>",
"   <p>",
"    Inflammation results from the proliferation of P. acnes. Sequencing of the P. acnes genome has led to the identification of the following bacterial properties that may contribute to the inflammatory response [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Enzymes produced by P. acnes may promote the degradation of the follicular wall and follicular rupture.",
"     </li>",
"     <li>",
"      P. acnes surface proteins may play a role in antigenicity, triggering humoral and cell-mediated immune responses.",
"     </li>",
"     <li>",
"      Heat shock proteins, which promote inflammation via the innate immune system, are produced by P. acnes.",
"     </li>",
"     <li>",
"      Porphyrins produced by P. acnes may contribute to adjacent tissue damage and inflammation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A component of the host innate immune system, the toll-like receptor, is also thought to play an important role in the P. acnes mediated inflammatory response [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/10\">",
"     10",
"    </a>",
"    ]. Toll-like receptor-2, located on perifollicular macrophages, binds to P. acnes, and triggers the release of proinflammatory cytokines (including IL-8 and IL-12) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/11\">",
"     11",
"    </a>",
"    ]. These cytokines contribute to the attraction of neutrophils and the release of neutrophil lysosomal enzymes that promote follicular rupture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23401?source=see_link\">",
"     \"Toll-like receptors: Roles in disease and therapy\"",
"    </a>",
"    .) Differences in the host inflammatory response to P. acnes or the pathogenicity of specific strains of P. acnes that colonize skin may contribute to the variation in the prevalence and severity of acne [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Types of acne lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The microcomedo is considered the precursor for the clinical lesions of acne vulgaris, including closed comedos, open comedos, and inflammatory papules, pustules, and nodules. The process by which microcomedones evolve into other acne lesions remains to be elucidated, but may involve the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Accumulation of sebum and keratinous material converts a microcomedo into a closed comedo (a whitehead) (",
"      <a class=\"graphic graphic_picture graphicRef62816 \" href=\"UTD.htm?38/41/39570\">",
"       picture 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The follicular orifice is opened with continued distension, forming an open comedo (a blackhead) (",
"      <a class=\"graphic graphic_picture graphicRef80536 \" href=\"UTD.htm?28/4/28739\">",
"       picture 1",
"      </a>",
"      ). Densely packed keratinocytes, oxidized lipids, and melanin all contribute to the dark color of the open comedo.",
"     </li>",
"     <li>",
"      Follicular rupture contributes to the development of inflammatory lesions. Following follicular rupture, proinflammatory lipids and keratin are extruded into the surrounding dermis, leading to inflammatory papule or nodule formation (",
"      <a class=\"graphic graphic_picture graphicRef68412 graphicRef70809 \" href=\"UTD.htm?38/51/39736\">",
"       picture 2A-B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Role of androgens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Androgens contribute to the development of acne through stimulating the growth and secretory function of sebaceous glands. Most circulating androgens are produced by the adrenal gland and the gonads (",
"    <a class=\"graphic graphic_figure graphicRef70372 \" href=\"UTD.htm?0/7/123\">",
"     figure 2",
"    </a>",
"    ). Androgen production also occurs within the sebaceous glands, which convert dehydroepiandrosterone sulfate (DHEA-S), an adrenal androgen precursor, to testosterone via the action of several enzymes (",
"    <a class=\"graphic graphic_table graphicRef68437 \" href=\"UTD.htm?8/12/8395\">",
"     table 1",
"    </a>",
"    ). Testosterone is subsequently converted to 5-alpha-dihydrotestosterone (DHT) via the action of type I 5-alpha reductase in the sebaceous gland.",
"   </p>",
"   <p>",
"    Androgen receptors that bind DHT and testosterone are present in the sebaceous glands and the outer root sheath keratinocytes of the follicular epithelium. DHT has greater affinity for androgen receptors than testosterone. Men with androgen insensitivity (lacking androgen receptors) do not produce sebum and do not develop acne, suggesting an important role of androgen receptors in the pathogenesis of acne [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infantile acne (with typical onset at age three to six months) occurs as a result of elevated levels of androgens produced by the immature adrenal gland in girls, and the immature adrenal gland and testes in boys. Androgen levels fall by age one to two, and acne subsequently improves. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/13/22745?source=see_link&amp;anchor=H6#H6\">",
"     \"Benign skin and scalp lesions in the newborn and young infant\", section on 'Neonatal acne'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/13/22745?source=see_link&amp;anchor=H7#H7\">",
"     \"Benign skin and scalp lesions in the newborn and young infant\", section on 'Infantile acne'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The onset of acne in children correlates with the rise in serum levels of DHEA-S that occurs as puberty approaches (adrenarche). Higher serum levels of DHEA-S are found in prepubertal girls with acne than in those without [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/15\">",
"     15",
"    </a>",
"    ]; those with the highest levels develop the most severe acne [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although androgen excess due to a variety of conditions can cause acne, the majority of patients with acne have normal androgen levels. Conditions in which hyperandrogenism is seen include polycystic ovarian syndrome, congenital adrenal hyperplasia, and adrenal or ovarian tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/28/24007?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathogenesis and causes of hirsutism\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     External factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Soaps, detergents, and astringents remove sebum from the skin surface but do not alter sebum production. Repetitive mechanical trauma caused by scrubbing with these agents may worsen the disorder by rupturing comedos, promoting the development of inflammatory lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/17\">",
"     17",
"    </a>",
"    ]. Thus, patients with acne should refrain from rubbing their faces or picking their skin.",
"   </p>",
"   <p>",
"    Turtlenecks, bra straps, shoulder pads, orthopedic casts, and sports helmets may all cause acne mechanica, in which occlusion of pilosebaceous follicles leads to comedone formation. Pomade acne is associated with the use of occlusive, oil-based hair products. (See",
"    <a class=\"local\" href=\"#H21903168\">",
"     'Acne cosmetica'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;A potential role for diet in acne is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. A study of 47,355 women in the Nurses' Health Study that used retrospective data collection to determine diet during high school found an association between acne and intake of milk [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/22\">",
"     22",
"    </a>",
"    ]. The authors suggested that natural hormonal components of milk or other bioactive molecules in milk could exacerbate acne [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Two subsequent large prospective cohort studies (one involving boys and the other involving girls) also reported an association of milk ingestion and acne [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. All three studies were questionnaire-based, requiring subjects to recall their dietary intake and self-diagnose acne and disease severity.",
"   </p>",
"   <p>",
"    A case-control study of 205 patients with clinician-confirmed moderate to severe acne and 358 controls with mild or nonexistent acne also found a possible association between milk consumption (more than three portions per week) and moderate to severe acne (odds ratio [OR] 1.78, 95% CI 1.22-2.59) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/26\">",
"     26",
"    </a>",
"    ]. Similar to the other studies, food intake history was assessed via a retrospective patient questionnaire. No randomized trials have evaluated the relationship between dairy products and acne.",
"   </p>",
"   <p>",
"    Other studies have suggested that insulin-like growth factor (IGF) may play a role in acne [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Milk consumption has been associated with increased levels of serum IGF [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/29\">",
"     29",
"    </a>",
"    ]. IGF is also increased by ingestion of high glycemic loads and could potentially link diet and acne. A 12-week randomized trial that compared low and high glycemic load diets in 43 male patients with acne found a greater reduction in lesion counts with the low glycemic load diet [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/30\">",
"     30",
"    </a>",
"    ]. However, the participants on that diet also lost more weight than those on the high glycemic load diet, so it is possible that the results were due to changes in weight rather than the composition of the diet.",
"   </p>",
"   <p>",
"    There is no reliable evidence that ingestion of chocolate is associated with an increased prevalence or severity of acne [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data on favorable effects of dietary factors such as zinc, omega-3 fatty acids, antioxidants, vitamin A, and dietary fiber on acne vulgaris are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/31\">",
"     31",
"    </a>",
"    ]. Further studies are necessary to determine the roles of these supplements in acne vulgaris.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24193345\">",
"    <span class=\"h2\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with close family members with acne are at increased risk for the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/26,32,33\">",
"     26,32,33",
"    </a>",
"    ]. Case-control studies have demonstrated a more than three-fold risk among individuals with affected first-degree family members [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/26,33,34\">",
"     26,33,34",
"    </a>",
"    ], and a large twin study of monozygotic and dizygotic twins also supported the heritable nature of acne [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/35\">",
"     35",
"    </a>",
"    ]. In cases of very severe acne, there is often a positive family history; but the role of genetics in mild acne is uncertain due to the almost ubiquitous occurrence in young adolescents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Stress",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients and clinicians commonly believe that psychological stress can exacerbate acne [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. A prospective cohort study in 94 secondary school students compared acne severity and sebum production at times of high stress (midterm examinations) and low stress (summer holidays) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/38\">",
"     38",
"    </a>",
"    ]. Sebum production did not appear to be related to stress, but acne severity, as assessed by an examiner blinded to the hypothesis of the study, did appear to be associated with stress, particularly in boys.",
"   </p>",
"   <p>",
"    Similarly, a study of 22 university students found that acne severity appeared to have some correlation with stress around the time of school examinations [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Receptors for corticotropin releasing hormone (CRH), a hormone involved in the stress response, are present in human sebaceous glands [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/40\">",
"     40",
"    </a>",
"    ]. Sebaceous gland cells exhibit stronger staining for CRH in acne-involved skin than in normal or uninvolved skin. Although additional studies are necessary, these findings suggest that the CRH system may participate in the occurrence of stress-exacerbated acne.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24192832\">",
"    <span class=\"h2\">",
"     Body mass index",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few studies have evaluated the relationship between weight and acne vulgaris, and study results vary on the connection between these factors [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/26,41-43\">",
"     26,41-43",
"    </a>",
"    ]. Whereas a case-control study of adolescents and young adults (ages 10 to 24) found a correlation between low BMI and a reduced risk for acne that was most evident among males [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/26\">",
"     26",
"    </a>",
"    ], a cross-sectional, survey-based study of young adults (ages 18 and 19) found a statistically significant association between rising BMI and increased risk for acne only among females [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acne vulgaris typically affects those areas of the body that have the largest, hormonally-responsive sebaceous glands, including the face, neck, chest, upper back, and upper arms. In addition to the typical lesions of acne vulgaris (eg, open comedones, closed comedones, and inflammatory lesions), scarring and postinflammatory hyperpigmentation can occur, which can be greatly distressing for patients. Postinflammatory hyperpigmentation is most common in patients with darker complexions, and an individual hyperpigmented macule may take several months or more to resolve without treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39370?source=see_link&amp;anchor=H36#H36\">",
"     \"Treatment of acne vulgaris\", section on 'Therapy for postinflammatory hyperpigmentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adult women may present with acne involving the lower face and neck that is often associated with premenstrual flares (",
"    <a class=\"graphic graphic_picture graphicRef81886 \" href=\"UTD.htm?0/35/565\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. These women, in particular, seem to benefit from hormonal therapies for acne [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/44\">",
"     44",
"    </a>",
"    ]. Premenstrual flares of acne appear to be more common in women over the age of 33 than in women aged 20 to 33 years [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44599?source=see_link\">",
"     \"Hormonal therapy for women with acne vulgaris\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no universal classification system for acne vulgaris; the extensive variety of clinical presentations would make it challenging to develop and implement such a system. A description of the actual lesions encountered will be most useful when considering management of acne.",
"   </p>",
"   <p>",
"    Young adolescents often have primarily comedonal acne consisting of noninflammatory lesions (closed",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    open comedones) involving the forehead, nose and chin. As the acne progresses, patients develop inflammatory lesions (papules, pustules, and nodules (",
"    <a class=\"graphic graphic_picture graphicRef62816 graphicRef70809 graphicRef68412 \" href=\"UTD.htm?18/49/19226\">",
"     picture 2A-C",
"    </a>",
"    )) Comedones can become extensive in some patients (",
"    <a class=\"graphic graphic_picture graphicRef80536 \" href=\"UTD.htm?28/4/28739\">",
"     picture 1",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p>",
"    Nodules are tender inflammatory acne lesions that are larger than 5 mm in diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/47\">",
"     47",
"    </a>",
"    ]. Nodular acne is sometimes inaccurately referred to as \"cystic\" or \"nodulocystic\" acne (",
"    <a class=\"graphic graphic_picture graphicRef57925 graphicRef59878 \" href=\"UTD.htm?16/6/16488\">",
"     picture 4A-B",
"    </a>",
"    ). In reality, true cysts are rare. Sinus tracts, which manifest as fluctuant linear lesions, are formed when nodules merge. These are seen in the most severe forms of acne and are difficult to treat (",
"    <a class=\"graphic graphic_picture graphicRef77862 \" href=\"UTD.htm?41/52/42830\">",
"     picture 5",
"    </a>",
"    ). The presence of scarring or postinflammatory hyperpigmentation is also assessed.",
"   </p>",
"   <p>",
"    Estimations of acne severity are patient-specific, and depend on a number of factors. The clinical type of lesions, presence of scarring, presence of draining lesions or sinus tracts, lack of therapeutic response, and the psychological impact of acne are some of the features taken into account [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/47\">",
"     47",
"    </a>",
"    ]. As an example, patients with inflammatory, nodular acne are often considered to have severe acne. Similarly, a patient without nodules but who has numerous inflammatory papules and pustules and notable scarring could also be classified as having severe disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Acne variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasionally, patients with acne vulgaris may exhibit variants of the disease, some of which require aggressive treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/44,48\">",
"     44,48",
"    </a>",
"    ]. These variants are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Acne fulminans",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of fever and arthralgias with an acute eruption of large inflammatory nodules and friable plaques with hemorrhagic crusts suggests the diagnosis of acne fulminans, a systemic disorder (",
"    <a class=\"graphic graphic_picture graphicRef64372 \" href=\"UTD.htm?39/22/40290\">",
"     picture 6",
"    </a>",
"    ). This rare condition affects adolescent males primarily. Lesions usually involve the trunk, but may be present elsewhere. Acne fulminans is associated with leukocytosis, an elevated erythrocyte sedimentation rate, proteinuria, and osteolytic lesions.",
"   </p>",
"   <p>",
"    Patients with acne fulminans can be treated with systemic glucocorticoids (0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    plus oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    or oral antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/49\">",
"     49",
"    </a>",
"    ]. Treatment regimens vary, but oral glucocorticoids should be initiated about four weeks prior to starting low-dose oral isotretinoin to prevent a flare of the condition [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/49\">",
"     49",
"    </a>",
"    ]. Oral isotretinoin is started at 0.5",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    or less and can be gradually increased. After several weeks of therapy, glucocorticoids are tapered as tolerated. In rare cases, treatment of acne vulgaris with isotretinoin can precipitate an acne fulminans-like eruption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Acne conglobata",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acne conglobata is a severe form of nodular acne that is most commonly seen in young males (",
"    <a class=\"graphic graphic_picture graphicRef55681 graphicRef75599 \" href=\"UTD.htm?35/54/36712\">",
"     picture 7A-B",
"    </a>",
"    ). Lesions are most prominent on the back, chest, and buttocks, but can also appear in other sites. Large draining lesions, sinus tracts, and severe scarring may occur. Systemic symptoms are absent. Treatments have included systemic antibiotics, intralesional glucocorticoids, systemic glucocorticoids, and surgical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/48\">",
"     48",
"    </a>",
"    ]. Patients can respond well to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    , although they may experience severe flares at the start of isotretinoin therapy. For this reason, lower doses of isotretinoin (0.5",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    or less) plus systemic glucocorticoids before or during isotretinoin therapy are often required [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     SAPHO syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis, and osteitis) is another rare disorder (",
"    <a class=\"graphic graphic_picture graphicRef68169 \" href=\"UTD.htm?22/32/23047\">",
"     picture 8",
"    </a>",
"    ). This diagnosis also requires systemic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2201?source=see_link&amp;anchor=H22#H22\">",
"     \"Major causes of musculoskeletal chest pain\", section on 'Sternocostoclavicular hyperostosis (SAPHO syndrome)'",
"    </a>",
"    .), and (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5592?source=see_link\">",
"     \"Treatment of musculoskeletal chest pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30393?source=see_link&amp;anchor=H24#H24\">",
"     \"Neutrophilic dermatoses\", section on 'SAPHO syndrome'",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     PAPA syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;PAPA syndrome (sterile pyogenic arthritis, pyoderma gangrenosum, and acne) is an autosomal dominant inflammatory disorder that is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15494?source=see_link&amp;anchor=H8#H8\">",
"     \"Periodic fever syndromes and other autoinflammatory diseases: An overview\", section on 'PAPA syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Gram-negative folliculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with pre-existing acne vulgaris who have been treated with long-term systemic antibiotics (usually tetracyclines) may develop gram-negative folliculitis. These patients exhibit an initial response to the oral antibiotic, followed by apparent resistance to the treatment and worsening of acne. Inflammatory papules, pustules, and nodules typically appear on perinasal skin and the central face. A culture of lesions will yield gram-negative organisms, such as Enterobacter, Klebsiella, Pseudomonas, Proteus, or Escherichia species. Patients are treated with antibiotics with gram negative coverage. Recalcitrant cases are managed with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    for four to five months [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Neonatal acne and infantile acne",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal acne (also called neonatal cephalic pustulosis) and infantile acne are distinct conditions. Neonatal acne appears within the first few weeks of life (",
"    <a class=\"graphic graphic_picture graphicRef56615 \" href=\"UTD.htm?29/8/29829\">",
"     picture 9",
"    </a>",
"    ); infantile acne usually appears around three to six months of age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/13/22745?source=see_link&amp;anchor=H6#H6\">",
"     \"Benign skin and scalp lesions in the newborn and young infant\", section on 'Neonatal acne'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/13/22745?source=see_link&amp;anchor=H7#H7\">",
"     \"Benign skin and scalp lesions in the newborn and young infant\", section on 'Infantile acne'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Acne excori&eacute;e des jeunes filles",
"    </span>",
"    &nbsp;&mdash;&nbsp;This scarring acne condition is often, but not always, seen in young women. Relatively mild acne comedones or inflammatory papules are chronically and obsessively picked and excoriated, leading to erosions and scarring (",
"    <a class=\"graphic graphic_picture graphicRef73615 \" href=\"UTD.htm?21/45/22228\">",
"     picture 10",
"    </a>",
"    ). An underlying psychiatric disorder can be associated, and treatment may involve antidepressants and psychotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Solid facial edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Solid facial edema (Morbihan's disease) is a rare complication of acne that presents as facial soft tissue edema and erythema. The condition may wax and wane in severity, but usually does not spontaneously resolve without treatment. Improvement with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/16/33024?source=see_link\">",
"     ketotifen",
"    </a>",
"    , systemic glucocorticoids, or clofazimine has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Particular attention to endocrine function is essential in the evaluation of acne vulgaris. A medication history should also be reviewed for acne-inducing drugs (",
"    <a class=\"graphic graphic_table graphicRef76762 \" href=\"UTD.htm?11/32/11787\">",
"     table 2",
"    </a>",
"    ). Skin should be examined carefully, since an assessment of the type and location of lesions is critical for determining the most appropriate treatments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Hyperandrogenism",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women, polycystic ovary syndrome (PCOS) is the most common cause of hyperandrogenism. This disorder is characterized by menstrual irregularity, hirsutism, acne, ovarian cysts, and varying degrees of insulin resistance and acanthosis nigricans (",
"    <a class=\"graphic graphic_picture graphicRef80117 \" href=\"UTD.htm?22/16/22788\">",
"     picture 11",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16490?source=see_link\">",
"     \"Clinical manifestations of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One study of 51 women with acne (ages 15 to 46) found that 39 percent had menstrual abnormalities and 37 percent had PCOS [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/51\">",
"     51",
"    </a>",
"    ]. These observations suggest that all women with the combination of acne and oligomenorrhea should be evaluated for PCOS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39495?source=see_link\">",
"     \"Diagnosis of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rapid appearance of acne in conjunction with virilization suggests an underlying adrenal or ovarian tumor. Patients with Cushing's disease or syndrome and late-onset congenital adrenal hyperplasia may also experience acne vulgaris. Evidence of virilization includes a deepening voice, decreased breast size, clitoromegaly, alopecia, oligomenorrhea, and hirsutism. These patients may require imaging studies of the adrenal glands and ovaries, and hormonal evaluation. Referral to an endocrinologist should be considered in these cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Cushing's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40071?source=see_link\">",
"     \"Adrenal hyperandrogenism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recommendations for initial screening tests for hyperandrogenism vary. DHEA-S, total testosterone, and free testosterone levels are reasonable initial tests. A 17-hydroxyprogesterone level may also be obtained to screen for late-onset congenital adrenal hyperplasia, in which elevated levels of DHEA-S may also be seen. Referrals to endocrinology and gynecology should be considered if abnormalities are noted. Patients should not be taking oral contraceptives during testing for hyperandrogenism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete list of medications, including vitamin supplements, should be obtained. Known causes of acne or acneiform eruptions include glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    , epidermal growth factor inhibitors, iodides, bromides, androgens, and other drugs (",
"    <a class=\"graphic graphic_table graphicRef76762 \" href=\"UTD.htm?11/32/11787\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/20/6474/abstract/52\">",
"     52",
"    </a>",
"    ]. Vitamins B2, B6, and B12 may also cause drug-induced acne. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Drug-induced acne'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H29\">",
"     'EGFR inhibitor acneiform eruption'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=see_link&amp;anchor=H31#H31\">",
"     \"Drug eruptions\", section on 'Halogenoderma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination should focus upon the skin and in women, evidence of hyperandrogenism. The type and location of lesions, scarring (",
"    <a class=\"graphic graphic_picture graphicRef67165 \" href=\"UTD.htm?38/2/38947\">",
"     picture 12",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef61382 \" href=\"UTD.htm?25/24/25984\">",
"     picture 13",
"    </a>",
"    ), and postinflammatory pigmentary changes (",
"    <a class=\"graphic graphic_picture graphicRef78119 \" href=\"UTD.htm?20/25/20885\">",
"     picture 14",
"    </a>",
"    ) should be noted. The skin examination is essential for determining the best treatment course for an individual patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39370?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of acne vulgaris\", section on 'Patient assessment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39370?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of acne vulgaris\", section on 'Overview of treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hirsutism or virilization should prompt further laboratory and imaging studies or referral. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/31/9721?source=see_link\">",
"     \"Evaluation of premenopausal women with hirsutism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although acne vulgaris is a common condition that clinicians may feel they can accurately diagnose, a variety of disorders need to be considered in the differential diagnosis. In addition, patients may present with acneiform eruptions, which have similar features, but are unrelated to acne vulgaris.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Non-acne dermatoses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some of the conditions in the differential diagnosis of acne include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Rosacea &mdash;",
"      </strong>",
"      Acne vulgaris is distinguished from acne rosacea by the presence of comedones and the absence of telangiectasias. Common features of rosacea include erythema, telangiectasias, and papules or pustules on the central face (",
"      <a class=\"graphic graphic_picture graphicRef59815 \" href=\"UTD.htm?15/3/15410\">",
"       picture 15",
"      </a>",
"      ). &nbsp;(See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36584?source=see_link\">",
"       \"Rosacea: Pathogenesis, clinical features, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Perioral dermatitis &mdash;",
"      </strong>",
"      Perioral dermatitis (also known as periorificial dermatitis) is characterized by small, grouped, erythematous papules in a perioral (or occasionally perinasal or periorbital) distribution (",
"      <a class=\"graphic graphic_picture graphicRef73779 \" href=\"UTD.htm?21/39/22131\">",
"       picture 16",
"      </a>",
"      ). When the perioral skin is involved, a rim of spared skin is usually seen around the vermilion border of the lip. &nbsp;(See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/55/9081?source=see_link\">",
"       \"Perioral (periorificial) dermatitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Sebaceous hyperplasia &mdash;",
"      </strong>",
"      Visible enlargement of sebaceous glands is termed sebaceous hyperplasia. It most commonly occurs in adults with a history of oily skin. These growths are umbilicated yellowish papules are most commonly found on the forehead and cheeks (",
"      <a class=\"graphic graphic_picture graphicRef57577 \" href=\"UTD.htm?33/23/34164\">",
"       picture 17",
"      </a>",
"      ). These lesions may resemble basal cell carcinomas.",
"     </li>",
"     <li>",
"      <strong>",
"       Pseudofolliculitis barbae and acne keloidalis nuchae &mdash;",
"      </strong>",
"      These two conditions occur most commonly in individuals of African origin, and are likely related to the configuration of the hair follicle. It is thought that short shaved or clipped hairs curl back towards the skin, penetrate the skin, and cause a foreign-body inflammatory reaction. Inflammatory papules and pustules occur, which may result in keloidal scarring as the lesions heal (",
"      <a class=\"graphic graphic_picture graphicRef69365 graphicRef76686 graphicRef58129 \" href=\"UTD.htm?38/23/39290\">",
"       picture 18A-C",
"      </a>",
"      ). The beard area (pseudofolliculitis barbae) and the nuchal area (acne keloidalis nuchae) are typically involved. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36343?source=see_link\">",
"       \"Pseudofolliculitis barbae\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1847?source=see_link\">",
"       \"Keloids\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Folliculitis &mdash;",
"      </strong>",
"      Staphylococcal, eosinophilic, or pseudomonal folliculitis may mimic inflammatory acne (",
"      <a class=\"graphic graphic_picture graphicRef72586 graphicRef82321 \" href=\"UTD.htm?10/18/10538\">",
"       picture 19A-B",
"      </a>",
"      ). Comedones are absent, and lesions are usually monomorphous, unlike the polymorphous lesion in different stages of development that are typical of acne. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/55/22387?source=see_link\">",
"       \"Folliculitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Keratosis pilaris &mdash;",
"      </strong>",
"      In this common condition, caused by keratotic follicular plugging, patients typically present with small follicular papules on the extensor surfaces of the upper arms or thighs (",
"      <a class=\"graphic graphic_picture graphicRef68488 graphicRef60786 \" href=\"UTD.htm?33/23/34168\">",
"       picture 20A-B",
"      </a>",
"      ). Erythema may be present. Lesions can also occur on the face, particularly in children. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28423?source=see_link&amp;anchor=H16#H16\">",
"       \"Approach to the patient with pustular skin lesions\", section on 'Keratosis pilaris'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Favre-Racouchot syndrome &mdash;",
"      </strong>",
"      Favre-Racouchot syndrome is a condition resulting from cutaneous photodamage (sun damage) seen in middle-aged or older adults. Open and closed comedones are found in areas of photodamage, usually on the lateral upper cheeks (",
"      <a class=\"graphic graphic_picture graphicRef59339 \" href=\"UTD.htm?32/24/33156\">",
"       picture 21",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Nevus comedonicus &mdash;",
"      </strong>",
"      A lesion presenting at birth or in childhood, in which grouped or a linear arrangement of comedones are noted.",
"     </li>",
"     <li>",
"      <strong>",
"       Adnexal tumors &mdash;",
"      </strong>",
"      Benign follicular tumors, such as trichoepitheliomas, trichodiscomas, or fibrofolliculomas typically present as flesh-colored facial papules.",
"     </li>",
"     <li>",
"      <strong>",
"       Steatocystoma multiplex &mdash;",
"      </strong>",
"      Steatocystoma multiplex is an autosomal dominant or sporadic genetic disorder in which multiple yellow or skin-colored sebum-filled cysts are found on the trunk, upper arms, or chest (",
"      <a class=\"graphic graphic_picture graphicRef71097 \" href=\"UTD.htm?15/49/16146\">",
"       picture 22",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Tuberous sclerosis &mdash;",
"      </strong>",
"      Facial angiofibromas associated with tuberous sclerosis usually appear in childhood. These lesions commonly present as persistent, 1 to 3 mm pink or red papules on the nose and medial cheeks (",
"      <a class=\"graphic graphic_picture graphicRef54868 \" href=\"UTD.htm?27/46/28384\">",
"       picture 23",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/38/34410?source=see_link\">",
"       \"Tuberous sclerosis complex: Genetics, clinical features, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Acneiform eruptions",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple disorders in which acne-like eruptions occur, unassociated with true acne vulgaris. These include the following:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Drug-induced acne",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-induced acne typically presents with a monomorphous inflammatory papular eruption (as opposed to the polymorphous eruption with lesions in varying stages seen with acne vulgaris) (",
"    <a class=\"graphic graphic_picture graphicRef59186 \" href=\"UTD.htm?8/3/8246\">",
"     picture 24",
"    </a>",
"    ). Medications associated with drug-induced acne are listed in a table (",
"    <a class=\"graphic graphic_table graphicRef76762 \" href=\"UTD.htm?11/32/11787\">",
"     table 2",
"    </a>",
"    ). Glucocorticoid-induced eruptions are also referred to as \"steroid folliculitis.\" (see",
"    <a class=\"local\" href=\"#H23\">",
"     'Medications'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21903168\">",
"    <span class=\"h3\">",
"     Acne cosmetica",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cosmetic products that contain comedogenic ingredients can induce the formation of acne lesions. This type of acne has lessened as products designed to be less comedogenic have become widely available. Heavy, oil-based hair products are still commonly used and may contribute to the development of acne on the forehead (pomade acne).",
"   </p>",
"   <p>",
"    Irritant reactions to cosmetic products can also produce eruptions that resemble acne vulgaris. Inflammatory papules or pustules may occur within hours after the application of the inciting product. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     EGFR inhibitor acneiform eruption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidermal growth factor receptor (EGFR) inhibitors and other tyrosine kinase inhibitors used to treat cancers are known to cause an inflammatory acneiform eruption involving the face, neck and upper trunk in the majority of patients receiving these medications (",
"    <a class=\"graphic graphic_picture graphicRef55753 \" href=\"UTD.htm?21/20/21827\">",
"     picture 25",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35834?source=see_link\">",
"     \"Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Occupational acne",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comedones, inflammatory papules, pustules, nodules, or cysts can occur in response to exposure to certain chemicals, including insoluble cutting oils,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/43/44724?source=see_link\">",
"     coal tar",
"    </a>",
"    derivatives, and chlorinated hydrocarbons. Chloracne is the term used to describe occupational acne that occurs with exposure to chlorinated hydrocarbons (eg, dioxin) via percutaneous contact, inhalation, or ingestion. Clinically, chloracne is characterized by large monomorphic comedones with evolution into severely inflammatory and scarring lesions. Chloracne is most common on the face, neck, postauricular skin, axillae, and scrotum, although other sites may be involved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Tropical acne",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tropical acne occurs upon exposure to elevated environmental temperatures, and may be seen in tropical countries or other situations (eg, occupations) in which individuals are exposed to extreme heat. Large inflammatory nodules are seen on the trunk and buttocks. Treatment involves avoidance of heat. Systemic antibiotics may also be used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Radiation acne",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with ionizing radiation can result in the appearance of comedones as acute radiation dermatitis resolves. Ionizing radiation induces follicular epithelial metaplasia, creating follicular hyperkeratotic plugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Apert syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apert syndrome (ie, acrocephalosyndactyly type I) is an autosomal dominant disorder associated with synostoses of bone in the hands, feet, cranium, and vertebral bodies. A diffuse acneiform eruption on the arms, buttocks, and thighs is seen. The acneiform eruption is difficult to treat.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     Isotretinoin",
"    </a>",
"    has been used with success in some cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8487?source=see_link&amp;anchor=H2#H2\">",
"     \"Craniosynostosis syndromes\", section on 'Apert syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/12/1218?source=see_link\">",
"       \"Patient information: Acne (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/40/20099?source=see_link\">",
"       \"Patient information: Acne (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acne vulgaris is a common condition in adolescents that also affects adults. The psychological impact of acne vulgaris can be significant. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acne vulgaris is a disorder of the pilosebaceous follicles. Follicular hyperkeratinization, sebum production, Propionibacterium acnes (P. acnes), and inflammation are involved in the pathogenesis. Follicular rupture, which releases proinflammatory lipids and keratin into the dermis, can intensify the inflammation seen in acne. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Androgens induce sebum production, and are an important factor in the development of acne vulgaris. Hyperandrogenism may cause acne in some patients, but most patients with acne vulgaris do not have androgen excess. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Role of androgens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The role of diet and stress in acne vulgaris remain unclear. A contributory effect of milk and high-glycemic index diets has been proposed, but prospective trials are necessary to ascertain the relationship between diet and acne. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diet'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Stress'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Typically, acne vulgaris occurs on areas of the body with hormonally-sensitive sebaceous glands, including the face, neck, chest, upper back, and upper arms. Open comedones, closed comedones, and inflammatory papules, pustules, or nodules may be seen. The term \"cystic acne\" is a misnomer, as true cysts are rare in acne vulgaris. Adult women may present with lower face and neck acne associated with premenstrual flares. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical manifestations and classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of uncommon acne variants exist. Highly inflammatory conditions such as acne fulminans and acne conglobata require aggressive therapy to prevent scarring. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Acne variants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of acne vulgaris rests upon the patient's history and physical examination. If virilization, menstrual irregularity, or hirsutism is seen in women presenting with acne, evaluation for hyperandrogenism is indicated. A medication history should evaluate for the use of drugs that may cause acne or acneiform eruptions. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although acne vulgaris is a common condition that is often easily diagnosed, clinicians should be mindful of other diagnostic possibilities, including acneiform eruptions. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H29\">",
"       'EGFR inhibitor acneiform eruption'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/1\">",
"      Cotterill JA, Cunliffe WJ. Suicide in dermatological patients. Br J Dermatol 1997; 137:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/2\">",
"      Dalgard F, Gieler U, Holm J&Oslash;, et al. Self-esteem and body satisfaction among late adolescents with acne: results from a population survey. J Am Acad Dermatol 2008; 59:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/3\">",
"      Newton JN, Mallon E, Klassen A, et al. The effectiveness of acne treatment: an assessment by patients of the outcome of therapy. Br J Dermatol 1997; 137:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/4\">",
"      Stathakis V, Kilkenny M, Marks R. Descriptive epidemiology of acne vulgaris in the community. Australas J Dermatol 1997; 38:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/5\">",
"      Collier CN, Harper JC, Cafardi JA, et al. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol 2008; 58:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/6\">",
"      Goulden V, Clark SM, Cunliffe WJ. Post-adolescent acne: a review of clinical features. Br J Dermatol 1997; 136:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/7\">",
"      Jeremy AH, Holland DB, Roberts SG, et al. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol 2003; 121:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/8\">",
"      Br&uuml;ggemann H, Henne A, Hoster F, et al. The complete genome sequence of Propionibacterium acnes, a commensal of human skin. Science 2004; 305:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/9\">",
"      Br&uuml;ggemann H. Insights in the pathogenic potential of Propionibacterium acnes from its complete genome. Semin Cutan Med Surg 2005; 24:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/10\">",
"      Shibata M, Katsuyama M, Onodera T, et al. Glucocorticoids enhance Toll-like receptor 2 expression in human keratinocytes stimulated with Propionibacterium acnes or proinflammatory cytokines. J Invest Dermatol 2009; 129:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/11\">",
"      Kim J, Ochoa MT, Krutzik SR, et al. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol 2002; 169:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/12\">",
"      Lomholt HB, Kilian M. Population genetic analysis of Propionibacterium acnes identifies a subpopulation and epidemic clones associated with acne. PLoS One 2010; 5:e12277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/13\">",
"      Sugisaki H, Yamanaka K, Kakeda M, et al. Increased interferon-gamma, interleukin-12p40 and IL-8 production in Propionibacterium acnes-treated peripheral blood mononuclear cells from patient with acne vulgaris: host response but not bacterial species is the determinant factor of the disease. J Dermatol Sci 2009; 55:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/14\">",
"      Imperato-McGinley J, Gautier T, Cai LQ, et al. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. J Clin Endocrinol Metab 1993; 76:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/15\">",
"      Lucky AW, Biro FM, Huster GA, et al. Acne vulgaris in premenarchal girls. An early sign of puberty associated with rising levels of dehydroepiandrosterone. Arch Dermatol 1994; 130:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/16\">",
"      Lucky AW, Biro FM, Simbartl LA, et al. Predictors of severity of acne vulgaris in young adolescent girls: results of a five-year longitudinal study. J Pediatr 1997; 130:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/17\">",
"      Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003; 49:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/18\">",
"      Cordain L, Lindeberg S, Hurtado M, et al. Acne vulgaris: a disease of Western civilization. Arch Dermatol 2002; 138:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/19\">",
"      Thiboutot DM, Strauss JS. Diet and acne revisited. Arch Dermatol 2002; 138:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/20\">",
"      Bershad S. The unwelcome return of the acne diet. Arch Dermatol 2003; 139:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/21\">",
"      Spencer EH, Ferdowsian HR, Barnard ND. Diet and acne: a review of the evidence. Int J Dermatol 2009; 48:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/22\">",
"      Adebamowo CA, Spiegelman D, Danby FW, et al. High school dietary dairy intake and teenage acne. J Am Acad Dermatol 2005; 52:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/23\">",
"      Danby FW. Acne and milk, the diet myth, and beyond. J Am Acad Dermatol 2005; 52:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/24\">",
"      Adebamowo CA, Spiegelman D, Berkey CS, et al. Milk consumption and acne in adolescent girls. Dermatol Online J 2006; 12:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/25\">",
"      Adebamowo CA, Spiegelman D, Berkey CS, et al. Milk consumption and acne in teenaged boys. J Am Acad Dermatol 2008; 58:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/26\">",
"      Di Landro A, Cazzaniga S, Parazzini F, et al. Family history, body mass index, selected dietary factors, menstrual history, and risk of moderate to severe acne in adolescents and young adults. J Am Acad Dermatol 2012; 67:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/27\">",
"      Thiboutot D. Acne: hormonal concepts and therapy. Clin Dermatol 2004; 22:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/28\">",
"      Cappel M, Mauger D, Thiboutot D. Correlation between serum levels of insulin-like growth factor 1, dehydroepiandrosterone sulfate, and dihydrotestosterone and acne lesion counts in adult women. Arch Dermatol 2005; 141:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/29\">",
"      Holmes MD, Pollak MN, Willett WC, Hankinson SE. Dietary correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiol Biomarkers Prev 2002; 11:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/30\">",
"      Smith RN, Mann NJ, Braue A, et al. The effect of a high-protein, low glycemic-load diet versus a conventional, high glycemic-load diet on biochemical parameters associated with acne vulgaris: a randomized, investigator-masked, controlled trial. J Am Acad Dermatol 2007; 57:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/31\">",
"      Bowe WP, Joshi SS, Shalita AR. Diet and acne. J Am Acad Dermatol 2010; 63:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/32\">",
"      Ballanger F, Baudry P, N'Guyen JM, et al. Heredity: a prognostic factor for acne. Dermatology 2006; 212:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/33\">",
"      Xu SX, Wang HL, Fan X, et al. The familial risk of acne vulgaris in Chinese Hans - a case-control study. J Eur Acad Dermatol Venereol 2007; 21:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/34\">",
"      Goulden V, McGeown CH, Cunliffe WJ. The familial risk of adult acne: a comparison between first-degree relatives of affected and unaffected individuals. Br J Dermatol 1999; 141:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/35\">",
"      Bataille V, Snieder H, MacGregor AJ, et al. The influence of genetics and environmental factors in the pathogenesis of acne: a twin study of acne in women. J Invest Dermatol 2002; 119:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/36\">",
"      Rasmussen JE, Smith SB. Patient concepts and misconceptions about acne. Arch Dermatol 1983; 119:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/37\">",
"      Green J, Sinclair RD. Perceptions of acne vulgaris in final year medical student written examination answers. Australas J Dermatol 2001; 42:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/38\">",
"      Yosipovitch G, Tang M, Dawn AG, et al. Study of psychological stress, sebum production and acne vulgaris in adolescents. Acta Derm Venereol 2007; 87:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/39\">",
"      Chiu A, Chon SY, Kimball AB. The response of skin disease to stress: changes in the severity of acne vulgaris as affected by examination stress. Arch Dermatol 2003; 139:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/40\">",
"      Ganceviciene R, Graziene V, Fimmel S, Zouboulis CC. Involvement of the corticotropin-releasing hormone system in the pathogenesis of acne vulgaris. Br J Dermatol 2009; 160:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/41\">",
"      Tsai MC, Chen W, Cheng YW, et al. Higher body mass index is a significant risk factor for acne formation in schoolchildren. Eur J Dermatol 2006; 16:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/42\">",
"      Halvorsen JA, Vleugels RA, Bjertness E, Lien L. A population-based study of acne and body mass index in adolescents. Arch Dermatol 2012; 148:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/43\">",
"      Galobardes B, Davey Smith G, Jeffreys M, et al. Acne in adolescence and cause-specific mortality: lower coronary heart disease but higher prostate cancer mortality: the Glasgow Alumni Cohort Study. Am J Epidemiol 2005; 161:1094.",
"     </a>",
"    </li>",
"    <li>",
"     Zaenglein AK, Thiboutot DM. Acne Vulgaris. In: Dermatology, 2nd ed, Bolognia JL, Jorizzo JL, Rapini RP, et al (Eds), Elsevier, 2008. p.495.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/45\">",
"      Lucky AW. Quantitative documentation of a premenstrual flare of facial acne in adult women. Arch Dermatol 2004; 140:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/46\">",
"      Stoll S, Shalita AR, Webster GF, et al. The effect of the menstrual cycle on acne. J Am Acad Dermatol 2001; 45:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/47\">",
"      Pochi PE, Shalita AR, Strauss JS, et al. Report of the Consensus Conference on Acne Classification. Washington, D.C., March 24 and 25, 1990. J Am Acad Dermatol 1991; 24:495.",
"     </a>",
"    </li>",
"    <li>",
"     Zaenglein AK, Graber EM, Thiboutot DM, et al. Acne vulgaris and acneiform eruptions. In: Dermatology in General Medicine, 7th ed, Wolff K, Goldsmith LA, Katz SI, et al (Eds), McGraw Hill, 2008. p.690.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/49\">",
"      Seukeran DC, Cunliffe WJ. The treatment of acne fulminans: a review of 25 cases. Br J Dermatol 1999; 141:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/50\">",
"      Suei Y, Taguchi A, Tanimoto K, et al. Case report. synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome. Dentomaxillofac Radiol 1996; 25:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/20/6474/abstract/51\">",
"      Timpatanapong P, Rojanasakul A. Hormonal profiles and prevalence of polycystic ovary syndrome in women with acne. J Dermatol 1997; 24:223.",
"     </a>",
"    </li>",
"    <li>",
"     Goldstein SM, Wintroub BU. Adverse Cutaneous Reactions to Medication: A Physician's Guide, CoMedica Inc, New York 1994. p.55.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 39 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-00FF42CD0A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_20_6474=[""].join("\n");
var outline_f6_20_6474=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pilosebaceous follicles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Types of acne lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Role of androgens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      External factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24193345\">",
"      Family history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Stress",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24192832\">",
"      Body mass index",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL MANIFESTATIONS AND CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Acne variants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Acne fulminans",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Acne conglobata",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - SAPHO syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - PAPA syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Gram-negative folliculitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Neonatal acne and infantile acne",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Acne excori&eacute;e des jeunes filles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Solid facial edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Hyperandrogenism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Non-acne dermatoses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Acneiform eruptions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Drug-induced acne",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21903168\">",
"      - Acne cosmetica",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - EGFR inhibitor acneiform eruption",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Occupational acne",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Tropical acne",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Radiation acne",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Apert syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/39\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/39|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/20/35146\" title=\"figure 1\">",
"      Pathogenesis acne vulgaris",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/7/123\" title=\"figure 2\">",
"      Adrenal steroid synthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/39|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/4/28739\" title=\"picture 1\">",
"      Acne open comedones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/18/5413\" title=\"picture 2A\">",
"      Acne mixed type",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/26/36258\" title=\"picture 2B\">",
"      Inflammatory acne",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/41/39570\" title=\"picture 2C\">",
"      Acne closed comedones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/35/565\" title=\"picture 3\">",
"      Postadolescent acne",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/25/41361\" title=\"picture 4A\">",
"      Acne nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/29/25044\" title=\"picture 4B\">",
"      Nodular acne - face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/52/42830\" title=\"picture 5\">",
"      Acne sinus tract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/22/40290\" title=\"picture 6\">",
"      Acne fulminans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/26/24995\" title=\"picture 7A\">",
"      Acne conglobata face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/48/8964\" title=\"picture 7B\">",
"      Acne conglobata",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/32/23047\" title=\"picture 8\">",
"      SAPHO syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/8/29829\" title=\"picture 9\">",
"      Neonatal acne",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/45/22228\" title=\"picture 10\">",
"      Excoriee des jeunes filles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/16/22788\" title=\"picture 11\">",
"      Hirsutism and acne in CAH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/2/38947\" title=\"picture 12\">",
"      Hypertrophic scars acne",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/24/25984\" title=\"picture 13\">",
"      Keloids from acne",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/25/20885\" title=\"picture 14\">",
"      Acne hyperpigmentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/3/15410\" title=\"picture 15\">",
"      Rosacea papulopustular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/39/22131\" title=\"picture 16\">",
"      Perioral dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/23/34164\" title=\"picture 17\">",
"      Sebaceous hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/61/41941\" title=\"picture 18A\">",
"      Pseudofolliculitis barbae 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/57/41874\" title=\"picture 18B\">",
"      Pseudofolliculitis barbae - hair loop",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/17/24856\" title=\"picture 18C\">",
"      Acne keloidalis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/19/35127\" title=\"picture 19A\">",
"      Staphylococcal folliculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/44/3780\" title=\"picture 19B\">",
"      Pseudomonal folliculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/26/18854\" title=\"picture 20A\">",
"      Keratosis pilaris dark skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/3/26672\" title=\"picture 20B\">",
"      Keratosis pilaris fair skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/24/33156\" title=\"picture 21\">",
"      Favre Racouchot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/49/16146\" title=\"picture 22\">",
"      Steatocystoma multiplex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/46/28384\" title=\"picture 23\">",
"      TSC angiofibromas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/3/8246\" title=\"picture 24\">",
"      Glucocorticoid-induced acne",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/20/21827\" title=\"picture 25\">",
"      EGFR inhbtr acneiform erupt",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/39|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/12/8395\" title=\"table 1\">",
"      Androgen production",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/32/11787\" title=\"table 2\">",
"      Causes drug induced acne",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40071?source=related_link\">",
"      Adrenal hyperandrogenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28423?source=related_link\">",
"      Approach to the patient with pustular skin lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/13/22745?source=related_link\">",
"      Benign skin and scalp lesions in the newborn and young infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16490?source=related_link\">",
"      Clinical manifestations of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8487?source=related_link\">",
"      Craniosynostosis syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35834?source=related_link\">",
"      Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39495?source=related_link\">",
"      Diagnosis of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=related_link\">",
"      Drug eruptions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=related_link\">",
"      Epidemiology and clinical manifestations of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/31/9721?source=related_link\">",
"      Evaluation of premenopausal women with hirsutism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/55/22387?source=related_link\">",
"      Folliculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44599?source=related_link\">",
"      Hormonal therapy for women with acne vulgaris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1847?source=related_link\">",
"      Keloids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/54/33639?source=related_link\">",
"      Light-based, adjunctive, and other therapies for acne vulgaris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2201?source=related_link\">",
"      Major causes of musculoskeletal chest pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30393?source=related_link\">",
"      Neutrophilic dermatoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/42/22184?source=related_link\">",
"      Oral isotretinoin therapy for acne vulgaris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/28/24007?source=related_link\">",
"      Pathogenesis and causes of hirsutism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/40/20099?source=related_link\">",
"      Patient information: Acne (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/12/1218?source=related_link\">",
"      Patient information: Acne (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15494?source=related_link\">",
"      Periodic fever syndromes and other autoinflammatory diseases: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/55/9081?source=related_link\">",
"      Perioral (periorificial) dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36343?source=related_link\">",
"      Pseudofolliculitis barbae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36584?source=related_link\">",
"      Rosacea: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23401?source=related_link\">",
"      Toll-like receptors: Roles in disease and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39370?source=related_link\">",
"      Treatment of acne vulgaris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5592?source=related_link\">",
"      Treatment of musculoskeletal chest pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/38/34410?source=related_link\">",
"      Tuberous sclerosis complex: Genetics, clinical features, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_20_6475="High PEEP vent";
var content_f6_20_6475=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F62961&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F62961&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Allowable combinations of positive end-expiratory pressure (PEEP) and fraction of inspired oxygen (FiO2) used in the high PEEP arm of the ALVEOLI trial",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"8\">",
"       High PEEP group",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       <strong>",
"        FiO2",
"       </strong>",
"      </td>",
"      <td>",
"       0.3",
"      </td>",
"      <td>",
"       0.4",
"      </td>",
"      <td>",
"       0.5",
"      </td>",
"      <td>",
"       0.5-0.8",
"      </td>",
"      <td>",
"       0.8",
"      </td>",
"      <td>",
"       0.9",
"      </td>",
"      <td>",
"       1.0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       <strong>",
"        PEEP",
"       </strong>",
"      </td>",
"      <td>",
"       12-14",
"      </td>",
"      <td>",
"       14-16",
"      </td>",
"      <td>",
"       16-18",
"      </td>",
"      <td>",
"       20",
"      </td>",
"      <td>",
"       22",
"      </td>",
"      <td>",
"       22",
"      </td>",
"      <td>",
"       22-24",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Brower, RG, Lanken, PH, MacIntyre, N, et al. Higher versus Lower Positive End-Expiratory pressures in Patients with the Acute Respiratory Distress Syndrome. N Engl J Med 2004; 351:327.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_20_6475=[""].join("\n");
var outline_f6_20_6475=null;
var title_f6_20_6476="Differential diagnosis acute knee pain athlete B";
var content_f6_20_6476=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58127&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58127&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of acute knee pain in the young athlete: part B",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mechanism of injury",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical Features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Lateral",
"pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"5\">",
"        LCL injury",
"       </td>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        Varus force",
"       </td>",
"       <td>",
"        Localized swelling and stiffness",
"       </td>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        Associated with superficial peroneal nerve injuries,",
"chondral injuries, and medial meniscal injuries",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Able to ambulate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Localized pain, swelling, ecchymosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain along course of ligament (examine in figure of 4",
"position)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laxity with varus stress and 30 degrees of knee flexion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"8\">",
"        Lateral",
"meniscal tear",
"       </td>",
"       <td colspan=\"1\" rowspan=\"8\">",
"        Twisting injury",
"       </td>",
"       <td>",
"        Usually able to ambulate, but weight bearing is limited",
"by pain",
"       </td>",
"       <td colspan=\"1\" rowspan=\"8\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Knee swelling and stiffness develop over two to three days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mechanical symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lateral pain with twisting or squatting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lateral joint line",
"tenderness&nbsp;&nbsp;&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Positive McMurray test",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Positive bounce home test",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased range of motion",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     LCL: Lateral collateral ligament.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_20_6476=[""].join("\n");
var outline_f6_20_6476=null;
var title_f6_20_6477="Perfluorochemical structures";
var content_f6_20_6477=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80558&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80558&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Perfluorochemical structures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 242px; height: 215px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The structure of two perfluorochemicals used for liquid ventilation is shown.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_20_6477=[""].join("\n");
var outline_f6_20_6477=null;
var title_f6_20_6478="IUD PI";
var content_f6_20_6478=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F56519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F56519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Tcu-380A (Paragard&reg;) intrauterine contraceptive device",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This device consists of a T-shaped polyethylene frame with 380 mm2 of exposed surface consisting of fine copper wire wound around the vertical stem and each of the horizontal arms. There is a 3-mm ball at the base of the stem to decrease the risk of cervical perforation [1]. A white or clear polyethylene monofilament string is knotted through this ball.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_20_6478=[""].join("\n");
var outline_f6_20_6478=null;
var title_f6_20_6479="CW Doppler AS mild";
var content_f6_20_6479=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73624&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73624&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mild aortic stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 273px; height: 228px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Continuous wave Doppler shows a peak velocity across the aortic valve of 2.7 m/sec or a gradient of 30 mm Hg, which is compatible with mild aortic stenosis. No aortic regurgitation is seen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Provided by Thomas Binder, MD, et al. Interactive Echocardiography. A Clinical Atlas. Futura, 1997.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_20_6479=[""].join("\n");
var outline_f6_20_6479=null;
